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ABSTRACT 
 
The molecular mechanisms and pathways responsible for the progression of 
hepatocellular carcinoma (HCC) remain to be fully characterized. Among the genetic 
lesions associated with HCC progression, Shukla et al. (2013) identified insertions of 
the L1 transposon proximal to the gene encoding the zinc-finger DNA-binding protein 
ST18 (suppression of tumorigenicity 18) and suggested that this actually functions as 
an oncogene in HCC. However, functional evidence for a cancer-promoting activity 
of ST18 and insight into its mode of action are missing. Here, I pursued the functional 
characterization of ST18 in a mouse model of HCC based on ex vivo transformation 
and subcutaneous transplantation of embryonic hepatoblasts. ST18 was undetectable 
in either normal liver or cultured hepatoblasts, but was induced in the subcutaneous 
tumors. ST18 was also expressed in either chronically or acutely inflamed mouse 
livers (as assessed in Mdr2-/- or LPS-treated mice) as well as in human Progressive 
Familial Intrahepatic Cholestasis 2 (PFIC2: a condition associated with chronic 
inflammation), suggesting its induction by inflammatory stimuli. The knockdown of 
ST18 delayed tumor formation or, if induced in already formed tumors, led to rapid 
hemorrhage, pervasive morphological changes in the tumor cells reminiscent of an 
epithelial-to-mesenchymal transition (EMT) and eventually tumor regression. RNA 
profiling revealed that ST18 silencing caused expression of EMT-associated genes, 
among others. Previous studies have linked inflammation to the induction of EMT in 
other epithelia: we hypothesize that the concomitant activation of ST18 constitutes a 
safeguard against EMT, inactivation of this control mechanism causing the dramatic 
phenotypic switch observed in our model. These data warrant further evaluation of the 
mode of action of ST18 and of its potential value as a therapeutic target in HCC. 
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1 INTRODUCTION 
 
1.1 Pathogenesis and treatment of Hepatocellular carcinoma (HCC) 
 
Hepatocellular carcinoma (HCC) is the most common primary form of liver cancer, 
followed by cholangiocarcinoma. With more than 750,000 new cases diagnosed every 
year, HCC represents the sixth most frequent cancer worldwide (Jemal et al., 2011) 
and the third most frequent cause of cancer-related death (Parkin et al., 2001), 
preceded only by lung and stomach cancer (Llovet and Bruix, 2003) and  HCC occurs 
predominantly in men and in elderly individuals. The etiological agents, including 
infection by viral hepatitis B (HBV) and C (HCV), alcohol abuse and aflatoxin 
exposure, are relatively well understood (Gomaa et al., 2008). Additionally, metabolic 
disorders such as obesity and diabetes are also considered risk factors (Gomaa et al., 
2008). The incidence of HCC is increasing due to the increasing frequency of HCV 
infection, while vaccination campaigns and antiviral treatment have diminished the 
occurrence of HBV-related HCC in the Western countries. Southeast Asia and sub-
Saharan Africa, where HBV infection is endemic, show the highest rates of HCC (El-
Serag, 2011). Liver cirrhosis and/or advanced fibrosis constitute the major clinical 
risk factors for the development of HCC present in 80% of cases (Severi et al., 2010). 
In particular, cirrhosis that origins from chronic liver injury provides a mutagenic and 
mitogenic environment that favors hepatocyte transformation leading to the HCC 
development. HCC is most frequently diagnosed at advanced stages, when limited 
therapeutic options are available. Moreover, it is a chemoresistant cancer, thus the 
only treatments existing so far are surgical resection or liver transplantation (Llovet 
and Bruix, 2003). Surgical intervention is effective for the treatment of patients with 
localized disease. However, over 80% of all patient present multifocal HCC, which 
limits the usefulness of this treatment. The phase 3 SHARP (Sorafenib HCC 
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Assessment Randomized Protocol) trial showed that Sorafenib, improved survival of 
patient with advanced HCC (Llovet et al., 2008). Sorafenib is a multikinase inhibitor 
that blocks the MAPK pathway and causes apoptosis in cancer cells as well as 
decreases angiogenesis, cell migration and proliferation (Llovet et al., 2008). In 2007 
the U.S. Food and Drug Administration (FDA) has approved the use of Sorafenib in 
patients with inoperable hepatocellular carcinoma, albeit treatment is often followed 
by the development of resistance. Recently, a combination of Sorafenib and Mapk14 
blockade emerged as a promising approach to increase therapeutic efficiency in 
human HCC (Rudalska et al., 2014) 
 
1.2 Histological aspects of HCC 
 
Recently the classification of HCC has shifted from a morphology-based approach to 
a functional clinical classification (such as the Barcelona-Clinic Liver Cancer staging 
system) centered on the stage of the disease related to treatment strategies  (Roncalli 
et al., 2010). In this chapter we will describe the histological patterns and the 
molecular markers used to diagnose and characterize HCC. 
HCC can be detected rapidly in sections stained with hematoxylin and eosin (H&E), 
and can be classified into three major histological patterns important for diagnostic 
purpose, albeit with little evidence that these morphological features have any 
biological and clinical significance. The classical histological patterns are: trabecular, 
pseudoglandular and solid (Fig. 1.1).  The trabecular pattern is the most common in 
well- and moderately differentiated HCCs. In this pattern, tumoral hepatocytes 
recapitulate normal liver cell plate of variable thickness that are separated by 
prominent sinusoidal endothelial cells. Pseudoglandular or acinar patterns are referred 
to as “pseudoglands” or “pseudoacini” because the gland-like structures are not true 
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glands but abnormal bile canaliculi formed between tumour cells. The solid pattern is 
basically a trabecular pattern but the sinusoid-like blood spaces are compressed into a 
compact mass, giving the tumour a solid appearance. The solid pattern is common in 
poorly differentiated tumours (Paradis, 2013). 
 
Figure 1.1: Histopathological subtypes of HCC. The three major architectural 
patterns in HCC are pseudoglandular, solid, trabecular. (Zender et al., 2005). 
 
The histopathology of murine liver cancer recapitulates that of human HCC. Zender et 
al. (2005) have shown that HCC arising from genetic manipulation of hepatoblasts 
were classified mostly as solid or solid/trabecular growth pattern and a small 
proportion resembled human pseudoglandular HCC. 
Clearly, morphologic criteria are not sufficient to well define HCC and the advent of 
the immunohistochemistry application has improved the diagnosis. A large variety of 
immunological markers of HCC have been described, including a number of highly 
specific markers such as albumin (ALB), fibrinogen, 1-anti-trypsin and alfa-
fetoprotein (AFP) (Paradis, 2013). An increased level of AFP strongly suggests HCC, 
although not all cases of HCC are associated with AFP elevation, which may also be 
found in other liver diseases.  In case of poorly differentiated tumors, the available 
markers are inadequate and additional markers would be useful. Finally, at the 
cellular level, HCC displays phenotypic traits of progenitor cells, retaining stem cell 
marker such as cytokeratin (CK) 19 that is expressed also in biliary epithelium 
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(Roncalli et al., 2010). Importantly, expression of CK19 in HCC is correlated with 
enhanced aggressiveness and poor prognosis. New immunological markers will allow 
a better characterization of the tumor and will provide useful information for the 
treatment of HCC patient.  
1.3 Genetic alterations in HCC 
 
Hepatocarcinogenesis is a multistep process in which multiple cancer-related genes 
are mutated. The molecular mechanisms and oncogenic pathways that are deregulated 
and/or mutated in HCC have not been completely elucidated, but are known to 
include changes in tumor suppressor genes, oncogenes, reactivation of developmental 
pathways and growth factors. Although many genetic alterations are present in HCC, 
the frequency of each individual gene modification is relatively low. Here, we will 
briefly discuss the major signaling pathways implicated in HCC such as p53, Wnt 
signalling, TGFβ, Myc. Finally, we will discuss new endogenous L1-mediated 
insertional mutagenesis as a potential source of mutation in HCC.  
p53 was dubbed as “the guardian of the genome” referring to its capacity to respond 
to cellular stress and DNA damage by inducing cell cycle arrest, hence permitting 
DNA repair, or apoptosis (Vousden and Lane, 2007). Based on its role in conserving 
genetic stability and preventing genome mutation, it is understandable why p53 is the 
most frequently altered gene during human carcinogenesis. However, compared to 
other solid tumors, mutations in p53 are relative rare in HCC and vary in different 
geographic areas, reflecting differences etiological agents. In sub-Saharan Africa and 
China, where aflatoxin B1 exposure is responsible for a high incidence of HCC, p53 
was frequently mutated (~50%), while p53 mutation is rare in HCC not induced by 
aflatoxin (Shiraha et al., 2013). A point mutation at the third position of codon 249 
resulting in a G:C to T:A transversion was shown to occur also in non-tumoral livers 
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and reflected the exposure to aflatoxin B1 in a dose dependent manner (Bressac et al., 
1991), indicating that this alteration is an early mutational event in 
hepatocarcinogenesis.  
Other major risk factors for developing HCC are viral hepatitis B and C, each 
associated with different p53 mutation profiles and frequencies: in HBV-related HCC, 
p53 mutation (45%) was significantly higher than that in HCV-related HCC (13%) 
(Teramoto et al., 1994). The p53 abnormality in HBV-related HCC is due to the viral 
HBX protein, encoded by HBV genome. The HBX protein binds to the C terminus of 
p53 in the cytoplasm, resulting in the blockage of p53 entry into the nucleus and 
inhibition of several critical p53-mediated cellular processes, including sequence-
specific DNA binding, transcriptional activation and apoptosis (Wang et al., 1994). 
The blockage of p53-mediated apoptosis, in particular, provides a selective advantage 
to preneoplastic hepatocytes (Arbuthnot et al., 2000). 
The Wnt/β-catenin pathway is another key regulator of tumor development and 
differentiation and has been shown to have an essential role in HCC. In particular, 
cytoplasm accumulation of β-catenin was shown to occur in 62% off all HCC, and to 
correlate with poor prognosis and tumor recurrence (Wong et al., 2001). 
The transforming growth factor beta (TGF-β) pathway has an important role in cell 
growth, differentiation and apoptosis. In the liver, TGF-β limits hepatocyte 
regeneration after injury by inhibiting DNA synthesis and inducing apoptosis 
(Oberhammer et al., 1992). TGF-β has been also described as tumor promoter by 
inducing epithelial to mesenchymal transition (EMT) that renders tumor cells more 
invasive (Giannelli et al., 2014). TGF-β has been reported frequently overexpressed in 
HCC, which correlated with increased tumor angiogenesis and poor prognosis (Teufel 
et al., 2007). A switch of TGF-β action during liver carcinogenesis from a tumor 
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suppressing effect to a tumor promoting function has been proposed. Especially, it has 
been shown that TGFβ induced apoptosis and EMT are mutually exclusive in 
physiological context, however in some conditions, TGFβ can induce apoptosis in a 
fraction of cells and simultaneously induce EMT in other cells meaning that 
hepatoblasts can respond differentially to the same factor (Song, 2007). 
The role of known oncogenes in liver tumor formation and progression has been 
widely studied, and in particular that of c-Myc. The association of c-Myc with liver 
carcinogenesis was first identified through the observation of high expression of c-
Myc in chronic liver disease and in HCC, by frequent c-Myc amplification in liver 
cancer tissue commonly seen in young patients with poor prognosis (Chan et al., 
2004). The overexpression of c-Myc in the liver of transgenic mice induced liver 
tumorigenesis and its inactivation was sufficient to induce tumor regression (Shachaf 
et al., 2004). 
L1 retrotransposon (long interspersed element 1) are autonomous mobile genetic 
elements and a source of endogenous mutagenesis in humans (Burns and Boeke, 
2012). Retrotransposons transpose DNA sequences through an RNA intermediate by 
a copy and paste mechanism (Hancks and Kazazian, 2012). L1 elements are present at 
more than 500000 copies in the human genome, but the majority are inactivated due 
to point mutations, rearrangement or truncation and just 80-100 elements are 
transposition-competent, and active in any individual (Brouha et al., 2003). L1 
insertions can alter gene structure and function and have been associated with 
hereditable and spontaneous retrotransposition events in different diseases (Faulkner, 
2011). Despite this capacity, until very recently, just few L1 insertions have been 
found in human tumors, and their possible causative role remained to be 
demonstrated. The first successful mapping of somatic L1 insertion was achieved in 
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colorectal tumors, where a single L1 insertion integrated within the APC gene was 
sufficient to drive oncogenesis (Miki et al., 1992). Recently, Shukla et al. (2013) have 
mapped L1 integration sites in a cohort of HCC patient using retrotransposon capture 
sequencing (RC-seq) and identified 12 de novo tumor specific L1 insertions. One of 
these somatic L1 insertions was shown to activate ST18 (Suppressor of 
Tumorigenicity 18), pointing to ST18 as a putative oncogene in liver cancer (Shukla 
et al., 2013). 
1.4 ST18 
 
The ST18 gene (Suppressor of Tumorigenicity 18) encodes a zinc-finger DNA-
binding protein, with six C2HC-type fingers arranged in two main clusters, each of 
which binding DNA (Yang et al., 2008) (Jandrig et al., 2004).  ST18 shows similarity 
to members of the NZF/MyT1 family of transcription factors (Yee and Yu, 1998), a 
nonclassical zinc finger family that plays an important role in the development of the 
central nervous system (Lee and Michel, 2014). Three proteins are part of this family: 
neural zinc finger factor-1 (NZF-1), myelin transcription factor-1 (Myt1) and ST18 
(NZF-3 or MYT3). ST18 is constitutively expressed in the brain, it has been reported 
to be upregulated during neuronal differentiation, and its overexpression in neuronal 
progenitor cells caused spontaneous differentiation (Kameyama et al., 2011).  
Despite the potential importance of ST18, little is known about its role and 
mechanisms of action in cancer, with contradictory reports on its pro- or anti-tumoral 
activities. ST18 was first described as tumor suppressor in breast cancer because of 
the strong correlation between hypermethylation of its promoter and loss of 
expression in tumor cells (Jandrig et al., 2004). ST18 is expressed at low levels in 
normal breast tissue, but is significantly down-regulated in primary breast tumors and 
in breast cancer cell lines (Jandrig et al., 2004). Ectopic ST18 expression in breast 
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cancer cells inhibits xenograft tumor formation and colony formation in soft agar, 
suggesting that ST18 behaves as a suppressor of tumor growth (Jandrig et al., 2004). 
Based on mRNA profiling and silencing with small interfering RNAs (siRNAs), it has 
been proposed that ST18 regulates pro-apoptotic and pro-inflammatory gene 
expression in human fibroblasts (Yang et al., 2008): accordingly, siRNA-mediated 
knockdown of ST18 reduced TNF-α induced apoptosis and pro-inflammatory gene 
expression, whereas its overexpression significantly increased apoptosis and 
expression of TNF-α, inteurleukin  (IL)-1α and IL-6 (Yang et al., 2008). These data, 
along with a recent paper on the pro-apoptotic action of ST18 in pancreatic β-cell 
(Henry et al., 2014), are consistent with a role in tumor suppression. Importantly, 
ectopic expression of the protein may cause artificial toxicity to the cells, and genetic 
proof that ST18 loss or reduction actively contributes to tumor progression - hence 
formal proof for a tumor suppressor activity of this protein - is missing so far. 
ST18 was significantly overexpressed in pediatric acute myeloid leukemia compared 
with healthy bone marrow, whilst its expression decreased to normal levels in patients 
with complete remission, pointing to ST18 as an oncogene with a diagnostic potential 
of becoming a new marker in leukemia (Steinbach et al., 2006). As mentioned above, 
in a recent paper by Shukla et al. (2013), L1-mediated insertional mutagenesis was 
shown to occur at the ST18 locus in human HCC, pointing to ST18 as a candidate 
oncogene in HCC (Shukla et al., 2013). The authors corroborated further the 
oncogenic function of ST18 showing that ectopic ST18 translation and transcription 
was seen in tumoral but not in control liver and frequent amplification of ST18 was 
observed in HCC nodules from Mdr2-/- mice (see below). However, a functional 
validation of ST18 as an oncogene in liver carcinogenesis is still missing. Following 
up from the report by Shukla and co-authors (2013), we have therefore embarked 
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upon the investigation of the role of ST18 during liver tumorigenesis and 
maintenance.  
1.5 Generation of genetically defined liver carcinoma 
 
Zender et al. (2005) developed a new mouse model of liver cancer based on ex vivo 
genetic manipulation of liver progenitor cells (hepatoblasts) followed by the 
transplantation of these cells into wild-type recipients. Practically, the authors isolated 
E-cadherin positive liver progenitors cells by indirect labeling, infected them with a 
combination of oncogenes (Myc or RAS) or short hairpin RNAs (shRNAs) directed 
against the tumor suppressor p53 (shp53) and finally transplanted these cells into 
immuno-compromised mice. Tumors arose rapidly and recapitulated the 
histopathology of human HCC, whilst immunohistochemistry confirmed their 
association with the liver lineage. 
Interestingly, depending from the embryonic day of hepatocyte purification, 
transduced hepatoblasts acquired different phenotypes. Embryonic hepatoblasts 
harvested from p53 deficient mouse fetal livers at embryonic day (E) 14.5 and 
transduced with a retrovirus encoding c-Myc (or H-Rasv12) rapidly acquired an 
immortal phenotype and generated spontaneous tumors when injected 
subcutaneously. On the contrary, when the same cells are harvested at a later stage 
(E18.5), c-Myc immortalizes, but does not transform them (Zender et al., 2005). 
Hence, these E18.5 p53-/-/c-Myc hepatoblasts provide a sensitized background to test 
whether overexpression of potential oncogenes or knockdown of putative tumor 
suppressors triggers tumorigenesis. As expected, H-Rasv12 could transform these 
immortalized hepatoblasts (Table 1.1).  
 
	   18	  
 
Table 1.1: Schematic of hepatoblast immortalization and transformation 
capacities.   
Hepatoblasts harvested from mouse fetal livers at different embryonic days and 
transduced with shp53 and/or c-Myc and/or H-Rasv12 rapidly acquire immortal or 
transform phenotypes, as indicated. 
 
 
To identify genes required for the proliferation or survival of cancer cells, several 
groups have performed genetic screens and related functional validation in this mouse 
models and in human HCC cell lines (Zender et al., 2006) (Huang et al., 2014; 




Inflammation is an immediate response of the immune system to infection and 
physical injury, aimed at restoring tissue homeostasis. Inflammation can be classified 
as acute or chronic, with the two forms being distinguished by their duration and the 
type of infiltrating inflammatory cells. Acute inflammation is an immediate protective 
response characterized by increased blood flow and leukocyte infiltration of the 
injured tissue, to remove the stimulus and repair the affected site. Chronic 
inflammation is a prolonged process acting as a favorable pre-neoplastic setting due 
to persistent aggressive stimuli that lead to more damage than healing. 
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Chronic inflammation and cancer have been linked for the first time by Rudolf 
Virchow in 1863, based on the presence of leukocytes within neoplastic tissue 
(Balkwill and Mantovani, 2001). This association has received growing support in 
recent years, as data revealing that inflammation is itself an important factor leading 
to cancer progression have accumulated (Hanahan and Weinberg, 2011). The 
relationship between inflammation and cancer consists of two pathways: an extrinsic 
pathway driven by inflammation or infection per se that increased cancer risk and an 
intrinsic pathway driven by genetic alteration that cause inflammation, and both can 
drive to neoplasia (Mantovani et al., 2008). The proof of the involvement of 
inflammation in cancer formation is starting to have implications for prevention and 
treatment. In particular, anti-inflammatory drugs have been reported to prevent or 
delay tumor progression in colon cancer (Wang and DuBois, 2013). Up to 15% of 
human cancers are associated with inflammation, while more than 90% of HCC cases 
originating from an inflammatory context as detailed above (Bishayee, 2014). 
Regardless the etiology (HBV,HCV, alcohol…), liver injury initiates in a background 
of inflammation that sequentially progresses through repeated cycles of apoptosis and 
regeneration, leading to epigenetic changes in the hepatocytes that finally culminate 
in neoplastic alterations (Cairo and Buendia, 2012). In particular, the neoplastic lesion 
in liver consecutively progresses from fibrosis to cirrhosis and finally culminates in 
HCC. Liver cirrhosis, which is linked to the development of the vast majority of cases 
of HCC, is characterized by a strong inflammatory response and the presence of 
senescent cells (Ramakrishna et al., 2013). 
Many molecules compose the inflammatory microenvironment involved in tumor 
initiation and progression. Specifically, cytokines such as interleukin (IL) 1β, IL6, 
interferon (IFN) γ or tumor necrosis factor (TNF) α, participate in chronic hepatic 
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inflammation. IL1β promotes tumorigenesis through increased angiogenesis and is a 
potent mediator of metastasis, which altered the interaction between tumor and 
endothelial cells by upregulating vascular adhesion molecule-1 (VCAM-1) and 
vascular endothelial growth factor (VEGF) (Sansone and Bromberg, 2011). IL6 
signaling leads to increased production of inflammatory cytokines through the 
activation of transcription factors such as NFkB (nuclear factor kappa-light-chain-
enhancer of activated B cells) and STAT3 (signal transducer and activator of 
transcription-3). Using Mdr2 knockout mice, a model of chronic inflammation that 
develops cholangitis, chronic liver inflammation and finally HCC (see below), it has 
been shown that the TNF-NFkB axis has a pro-carcinogenic effect on the liver: 
inhibiting the NF-kB circuitry by treatment with anti-TNF-α prevented inflammation 
and inhibited tumor progression (Pikarsky et al., 2004). STAT3 was also reported as a 
crucial link between inflammation an HCC progression (He and Karin, 2011). 
Interestingly, STAT3 is activated in human HCC but not in the surrounding normal 
hepatocytes and has been shown to increase the capacity of tumors to suppress the 
immune response (He and Karin, 2011; Kortylewski et al., 2005). Whatever the 
etiology, activation of NF-kB and STAT3 have been shown to be frequent and early 
events that contribute to the acquisition of a transformed phenotype during 
hepatocarcinogenesis (Liu et al., 2002). 
Although the existence of a link between liver inflammation and tumorigenesis is 
certain, little is known on the cellular pathways and the role of epigenetic changes 
involved in the inflammatory cascade in HCC. In an attempt to study the effects of 
acute inflammation in vivo, a model based on the inflammatory potential of 
lipopolysaccharide (LPS) was devised. LPS is a component of the cell wall of gram-
negative bacteria that causes polyclonal activation of B cells and stimulates 
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accumulation of macrophages and induces release of many inflammatory cytokines 
such as IL1b, TNF-a, TGFb and IL-6, leading to acute inflammatory response (Zhong 
et al., 2006). To study chronic liver inflammation many mouse models have been 
used, including the Mdr2-/- mice, the outline of which we will given later on. 
Finally, in this work we will describe experiments aimed at the validation of the role 
of our gene of interest based on either acute and chronic inflammation model.  
1.7 Progressive familial intrahepatic cholestasis (PFIC) 
 
Progressive familial intrahepatic cholestasis (PFIC) is a rare autosomal recessive 
disorder that manifests itself in the neonatal period, characterized by a cholestasis of 
hepatocellular origin that progresses to fatal liver failure during childhood. PFIC is a 
rare disease with an estimated incidence that varies between 1 every 50.000 and 
100.000 births, with no geographical or gender preference (Davit-Spraul et al., 2009). 
PFIC comes in three types of autosomal recessive disease: PFIC1, PFIC2 and PFIC3, 
respectively mutated in the hepatocyte membrane transporter genes ATP8B1, 
ABCB11 and ABCB4 (Fig.1.2). ABCB11, a bile salt export pump, and ABCB4, a 
phosphatidylcholine (PC) floppase, are both members of the ATP binding cassette 
(ABC) family and transport the two major components of bile, bile salt and PC, 
through the membrane using ATP hydrolysis to pump against a substrate 
concentration gradient. ATP8B1 also known as FIC1, encodes for a P-type ATPase, 
and appear to flip a membrane phospholipid, phosphatidylserine (PS), in the opposite 
direction (Davit-Spraul et al., 2009; Nicolaou et al., 2012). An effective transport 
system is required for the removal of cholesterol, which is insoluble in water, bile 
acids and phospholipids (Kubitz et al., 2012). Alteration of bile acid excretion from 
hepatocytes into bile ducts due to an increase in hepatic and serum levels of bile salts, 
leads to chronic liver damage and to the early onset of hepatocellular carcinoma. 
	   22	  
Figure 1.2: Progressive Familial Intrahepatic Cholestasis scheme.  The three 
different types of autosomal recessive disease: PFIC1, PFIC2 and PFIC3 are mutated 
in the hepatocytes membrane transporter genes ATP8B1, ABCB11 and ABCB4, 
respectively, leading to different transport defect. BA: bile acid, PC: 
phosphatidylcholine (Davit-Spraul et al., 2009) 
 
The common outcome of all PFIC types is cirrhosis and severe liver failure within the 
second decade of life. Patients with PFIC1, due to ATP8B1 deficiency, generally have 
canalicular cholestasis, and compared to PFIC2-3 the liver biopsies reveal mild liver 
damage, with a preserved lobular architecture and absence of giant cells (Clayton et 
al., 1969). PFIC1 is also known as Byler disease, electron microscopy revealing the 
so-called “Byler bile”, granular bile accumulated in the hepatocytes. The serum levels 
of hepatic enzymes routinely screened as markers of hepatic damage, gamma-
glutamyltranspeptidase (γ-GT) and alanine aminotransferase (ALT), are only mildly 
elevated in PFIC1 patients. The ATP8B1 gene is expressed in various tissues 
including liver, pancreas, cochlear hair cells and intestine: hence, unlike PFIC2 and 3, 
PFIC1 shows several extrahepatic symptoms such as pancreatitis, hearing loss and 
chronic diarrhea (Davit-Spraul et al., 2009).  
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PFIC2 patients have mutations in the ABCB11 gene, which encodes for a bile salt 
export pump, the principal conveyor of bile acids from the hepatocyte cytoplasm into 
the bile canaliculus. Mutations in this protein are responsible for the decreased bile 
salt secretion that leads to reduced bile flow and accumulation of bile salts inside the 
hepatocytes. As a consequence, patients have very low biliary bile salts but 
abnormally high serum bile salts. The levels of γGT and cholesterol in PFIC2 patients 
are normal but they have elevated serum ALT activity (Nicolaou et al., 2012). PFIC2 
is the most severe form of PFIC and is the only form of PFIC that has been reported 
to degenerate into hepatocellular carcinoma or cholangiocarcinoma. Histologically, 
pre-tumoral PFIC2 livers are characterized by giant cell hepatitis, bile duct 
proliferation and portal fibrosis (Chan and Vandeberg, 2012). 
The third type of PFIC, called PFIC3, is caused by genetic mutation in the ABCB4 
gene, encoding a phospholipid floppase involved in biliary PC secretion. The ABCB4 
gene, also called multidrug resistance-3 (MDR3) is the ortholog of the gene abrogated 
in Mdr2-/- mice and will be described later on. PFIC3 is characterized by increased 
γGT levels (Kubitz et al., 2012) and total absence of biliary PC. Liver histology 
reveals bile duct proliferation, portal fibrosis and biliary cirrhosis at advanced stage 
but no liver tumors have been related to PFIC3 (Chan and Vandeberg, 2012).  
 
1.8 Mouse models of PFIC 
 
As previously mentioned, PFIC2 is the only PFIC associated with liver cancer, with a 
tumorigenic process that follows a progression from dysplasia, through adenoma to 
HCC. Undoubtedly, the generation of a mouse model that mimics this spontaneous 
hepatocarcinogenesis would be really advantageous for the study of involved genes. 
Unfortunately, ABCB11 knockout mice display a less severe phenotype and do not 
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develop HCC (Lam et al., 2005). In these mice the total output of bile salts is 
unaffected due the compensatory role of another ABC transporter, ABCB1A 
otherwise unaffected in PFIC2 patients (Lam et al., 2005). Instead, Mdr2-/- mice 
(FVB.129P2-Abcb4tm1Bor) represent a model of chronic inflammation and spontaneous 
hepatocarcinogenesis that shares a very close etiologic background with PFIC2, even 
though Mdr2 is the ortholog of the human MDR3 gene, mutated in PFIC3, which in 
humans is not associated with a progression to HCC.  
The Mdr2 P-glycoprotein is present in the bile canalicular membrane of hepatocytes 
suggesting a role in biliary excretion (Smit et al., 1993): this protein is a transporter 
that functions as a flippase, translocating PC phospholipids from the inner to the outer 
leaflet of the hepatocytes canalicular membrane (Smit et al., 1993). In the absence of 
PC translocation activity, as in Mdr2-/- mice, there is no lipid secretion, persistent 
biliary epithelium damage induced by high concentrations of monomeric bile salts, 
and a consequent inflammatory response, followed by HCC (Fickert et al., 2004; 
Mauad et al., 1994). In Mdr2-/- mice tissues other than the liver have not shown any 
abnormalities. The liver looked anatomically normal until the second week after birth, 
when structural differences became clear in hepatocytes, with an increased number of 
acidophilic bodies, nuclear polymorphism and abnormally high proliferative activity 
and mitotic figures (Smit et al., 1993). Changes were not limited to the hepatocytes, 
but also the bile ducts were affected. The bile ducts showed persistent biliary 
epithelium damage, due to regurgitation of bile acid into portal interstitium and 
consequent inflammation and slight fibrosis (Smit et al., 1993). Mdr2-/- mice develop 
liver tumors following chronic inflammation in the early stage (8 weeks) 
characterized by extensive portal inflammation with mixed inflammatory infiltrates, 
rich in CD3+ cells, bile duct hyperplasia and hepatomegaly (Pikarsky et al., 2004). 
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From 4 months of age mdr2-/- mice start to develop preneoplastic lesions in the liver, 
and start to be affected by severe architectural and cytological liver dysplasia. 
Between 12 and 16 months of age, Mdr2-/- livers show multiple adenomatous lesions 
that progress to carcinoma (Katzenellenbogen et al., 2007) (Fig 1.3). 
 
 
Figure 1.3: Dynamic changes in Mdr2-/- livers. Panel a. Livers of WT and KO 
mice at 4/10/12 months. Mdr2-/- mice develop hepatocellular carcinoma (indicated by 
arrowheads) after chronic hepatitis at shorter time points (4-10 month). Panel b. H&E 
stained sections from livers from WT and KO mice. At 4 months, inflammation is 
prominent, at 10 months there is severe architectural and cytologic dysplasia and 
HCC develops after 12 months .Modified from (Pikarsky et al., 2004). 
 
We will take advantage of this well characterized model of inflammation-associated 
HCC using immunohistochemical analyses to study the induction of our candidate 
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1.10 Aim of the project 
 
The molecular mechanisms and pathways responsible for the progression of 
hepatocellular carcinoma (HCC) remain to be fully characterized. Among the genetic 
lesions associated with HCC progression, Shukla et al. identified insertions of the L1 
transposon proximal to the ST18 (suppression of tumorigenicity 18) locus and 
suggested that ST18 actually functions as an oncogene in HCC (Shukla et al., 2013). 
Despite the potential importance of ST18 little is known about its role and 
mechanisms of action in cancer, with contradictory reports on its pro- or anti-tumoral 
activities. ST18 was depicted as tumor suppressor in breast cancer (Jandrig et al., 
2004) and as an oncogene in acute myeloid leukemia (Steinbach et al., 2006), but 
functional validation is missing in either case, precluding definitive understanding of 
the contribution of ST18 to tumor progression. The aim of this project was to 
functionally validate the oncogenic function of ST18 in HCC and, having done so, to 
characterize it at the molecular level. To this end, we have taken advantage of an ex-
vivo model of liver carcinoma described previously by Zender et al. (2005). This 
approach is based on genetic manipulation of liver progenitor cells purified from 
mouse embryos and their seeding into recipient mice, resulting in the development of 
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2 MATERIALS AND METHODS 
 
2.1 Isolation, culture and retroviral infection of liver progenitor cells. 
 
We derived hepatoblasts from different strains of mice: C57/JHsd mice (Harlan 
laboratories), TRP53/C57 mice (Jackson laboratories), RERT2 (from Barbacid group, 
CNIO) following this protocol. 
Liver cell suspensions from fetal livers of E 14.5-18.5 mice were diced and treated 
with Dispase (Gibco) 1000U/ml for one hour at 37C°.  The livers were dispersed into 
single cells by pipetting and filtrated trough a nylon mesh filter (pore size,100um). 
The cellular pellet was washed with hypotonic lysis buffer (150 mM NH4Cl 10 mM 
KHCO3 100 µM EDTA) for 3 min at 4°C, than centrifuge and put in ice.  
Purification of E-cadherin positive hepatoblasts was performed using the MACS® 
magnetic cell sorting system (Miltenyi) through indirect labeling with the rat anti-
mouse E-cadherin (ECCD-1) antibody (Calbiochem). Because E-cadherin is 
exclusively expressed on the cell membrane of hepatoblasts, we could obtain a highly 
pure population from the initial liver suspension. 
Before loading onto MACS MS size column liver cell suspension were incubated 
with the antibody complex for 45 minutes at 4C°. Previously 4µg of ECCD-1 were 
incubated with 20µl of immunomagnetic beads at room temperature for one hour. 
Cells eluted were plated in laminin-coated plate (Sigma) in DMEM (Lonza) 10% FBS 
NA supplemented with HGF (40ng/ml Peprotech), EGF(20 ng/ml Peprotech) and 
Dexamethasone (10-6M sigma). 
After 48h cultured hepatoblasts were transduced with a combination of retrovirus co-
expressing c-myc, inactivated p53 (sh-p53), oncogenic RAS (H-RasV12). 
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Others plasmid used for hepatoblasts transduction were: MSCV-ST18-FLAG-IRES-
GFP, MSCV-LSL-ST18-FLAG, MLP-shST18, TtRMPVIR shST18. 
Briefly, retrovirus were produced in Phoenix packaging cells and collected in 
hepatocyte growth medium. Supernatant was passed through a 0.45 µm filter and 
supplemented with polybrene (2µg/ml). The infection procedure was repeated three 
times every 4 hours, then we add fresh medium supplemented with HGF (40ng/ml 
Peprotech), EGF (20 ng/ml Peprotech) and Dexamethasone (10-6M sigma). 
 
To activate the MSCV-LSL-ST18-FLAG we added 500nM 4-Hidroxytamoxifen (4-
OHT) (H7904 Sigma) in the medium of s and we checked for Cre recombination after 
72 hours by pcr using the following primers Fw: 
CCCTTGAACCTCCTCGTTCGACC Rv: TTATCTTCAACCTCGGCATCC. As 
control, we added 50µg/ml of TAT-Cre (home made) in Optimem (Life technologies) 
for 2 hours, and then we add the normal hepatoblast medium.  
2.2 Generation of subcutaneus tumors. 
 
3x105 genetically modified hepatoblasts in 0.3ml of PBS were injected 
subcutaneously in CD1-NUDE-HO (Charles River). Animals were monitored for 
signs of disease and tumor size was measured using a caliper.  
2.3 Doxycycline treatment 
 
CD1- nude mice injected with the conditional vector (TtRMPVIR shST18) to silence 
ST18 were treated with Doxycycline to activate the knock down of ST18. Mice were 
fed with 625mg/kg Doxycycline containing food (Mucedola). In some experiment we 
had also administrate the first hit of 200mg/ML Doxycycline (Sigma) in 300ul of 
water by oral gavage. 
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2.4 LPS treatment 
 
C57/JHsd mice were injected intraperitoneally with 100 µg of lipopolysaccharide 
(LPS) and sacrificed after 24h of treatment. Liver portion were dissected from 
pathological analysis. 
2.5 Pathological and immunohistochemistry analysis 
 
Tumors or liver portions assigned to histological assessment were fixed in 4% 
formaldehyde overnight. The next day the sample was washed in 70% ethanol and 
submitted for paraffin embedding. 5 um sections were stained with hematoxilin/eosin, 
and submitted for inspection to a mouse pathologist (Enrico Radaelli, VIB Center for 
the Biology of Disease, KU Leuven Center for Human Genetics, Belgium, and 
Camilla Recordati, Fondazione Filarete, Milan Italy). 
Human samples in the study were obtained from FFPE material from 4 children 
diagnosed with PFIC2-related HCC or chirrosis. All specimens were obtained at 
native-liver hepatectomy during transplantation at Ospedali Civici di Bergamo 
(Italy).FFPE material from Mdr2-/- mice were obtained from Natoli laboratory (IEO, 
Milan, Italy). 
Immunohistochemistry analysis was performing following this protocol. Briefly, 5 um 
sections were de-waxed and re-hydrated through an ethanol scale, heated in EDTA 
o,25mM ph9 (Dako #S2368)or citra solution (BioGenex #HK086-9K) in a water bath 
at 99°C for 30 minutes for antigen de-masking and left to cool down for 20 min. 
Washed once in water and after 5 minutes of treatment with 3% H2O2 for quenching 
of endogenous peroxidases, slides were incubated with the primary antibody (Table 
2.1) in a blocking solution (2% BSA, 2% goat serum, 0.02% Tween20, in TBS 1x) for 
3h RT. After primary incubation, slides were washed twice with TBS 1x, and 
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incubate with the secondary antibody (DAKO Cytomation Envision System Labelled 
Polymer-HRP) for 45 minutes. After washed twice with TBS 1x were developed with 
peroxidase substrate solution with DAB (DAKO) for 2-10 minutes. Slides were 
finally counterstained with hematoxylin, de-hydrated through alcoholic scale and 
mounted with Eukitt. 
 
Primary Ab Species Dilution Unmasking Code/Company 
polyclonal anti-
Albumin 
Chicken 1:400 Citrate #106582 Abcam 
polyclonal anti-α-
fetoprotein 
Rabbit 1:800 ------- #0008 Dako 
Monoclonal 
cytokeratin 19 





Rabbit 1:200 Citrate #86563 Abcam 
Monoclonal Ki-67 Mouse 1:500 Citrate #M7249 Dako 




Goat 1:200 EDTA #6458 Santa 
Cruz 
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2.6 RNA extraction and analysis 
 
Frozen tissue samples were homogenized with a dounce homogenizer or with 
GentleMACS Dissociator (Miltenyi Biotec), depending on the tissue volume, prior to 
column extraction. DNA from formalin-fixed, paraffin-embedded (FFPE) samples 
was purified with the AllPrep DNA/RNA FFPE kit (Qiagen). RNA was extracted in 
Trizol (Invitrogen) using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. 0.5 ug of total RNA was used for cDNA synthesis (using 
the ImProm-II Reverse Transcriptase, Promega), and 1 µl of the obtained cDNA was 
generally used as template for qPCR expression analyses. Quantification was 
performed on Nanodrop, and quality was assessed on Bioanalyzer (Agilent). 
1 µl cDNA from each reaction was used for qRT-PCR using the mouse ST18 primers 
(F’ GAAAACGGCACATTGGACTT;R’ GGTGAGGAAGTTGGGGGTAT). 
qRT-PCR (SYBR-green) analysis was performed on an Applied Biosystems 7500 
Real-time PCR system. Values were normalized to RPPO (F’ 
TTCATTGTGGGAGCAGAC; R’ CAGCAGTTTCTCCAGAGC). 
For RNAseq, RNA quality was assessed using the BioAnalyser 2100. For each 
sample, 5µg of total RNA were depleted of ribosomal RNA with the Ribo-ZeroTM 
rRNA Removal Kit from Epicentre®. Ribosomal RNA removal was checked using 
the BioAnalyser 2100. RNAseq libraries were prepared with the Illumina TruSeq 
RNA sample preparation kit v2 following the manufacturer’s protocol. Briefly, RNA 
was fragmented and cDNA was synthesized, end-repaired and 3’-end-adenylated. 
Following adapter ligation, libraries were amplified by PCR for 15 cycles. Libraries 
with distinct TruSeq adapter index were multiplexed (3 libraries per lane) on a HiSeq 
2000 and sequenced for 50 bases in the paired-end mode. Deseq2 was used to analyze 
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RNAseq data. RNA seq  duplicates were eliminated using rmdup function from the 
suite samtools (http://samtools.sourceforge.net/). Genes were hierarchically clustered 
with the R function hclust. Functional annotation was performed using the Gene 
Ontology categories of the bioinformatics tool Gene Set Enrichment Analysis 
(GSEA) based on Molecular Signatures Database (MSigDB). QIAGEN'S Ingenuity 
Pathway Analysis (IPA) was, also, used to interpreted the biological meaning. 
2.7 Immunoblotting 
 
Tumor tissue or cell pellets were lysed with 20mM HEPES at pH 7.5, 300mM NaCl, 
5mM EDTA, 10%Glycerol, 1% Triton X-100 supplemented with protease inhibitors 
(Mini, Roche) using a tissue homogenizer. Equal amounts of protein (50µg) were 
separated on 10% SDS-polyacrylamide gels and transferred to PVDF membranes. 
The blots were probed with antibodies against: anti-FLAG (1:8000 Sigma), anti-GFP 
(1:1000 home-made), Vinculin (1:10000 Sigma) anti ST18 (1:1000 Abcam). 
2.8 Flow cytometry  
 
Hepatoblasts GFP tagged were not fixed and directly monitored by flow cytometry. 
Single cell suspension was resuspended in PBS. Cells were analyzed using a 
FACSCalibur (Becton-Dickinson; Mountain View, CA) flow cytometer. GFP-
expressing cells were detected using the FL1 channel (absorption spectra 530/30 nm).  
Before doing FACS analysis from tumors, to verify the presence of Venus, tumors 
were diced and treated with dispase (Gibco) 1000U/ml for one hour at 37C° and 
dispersed into single cells by pipetting and filtrated trough a nylon mesh filter.  All 
FACS data were analyzed by using FlowJo software (TreeStart). 
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2.9 Colony forming assay 
 
In vitro, transformation assay was performed by placing a cell suspension into a semi-
solid medium, such as methylcellulose, MethoCult™ SF M3236, followed by 
incubation at 37°C for periods ranging from a few days to several weeks. In detail 
5.000 hepatoblasts resuspended in 250uL of hepatocytes growth medium were added 
to 1250uL of Methylcellulose stock (9 mL of MethoCult, P/S 100 uL, Glutammine 
100 uL, (10%)FBS NA 1mL).  The suspension was placed in a 6-well plate untreated 
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3 RESULTS 
 
3.1 Generation of hepatocellular-like carcinomas from transplanted liver 
progenitor cells  
 
To pursue the functional validation of genes involved in the initiation, progression or 
maintenance of HCC we initially set up an appropriate experimental system to model 
HCC in mice: this was based on previously published work (Zender et al., 2005), and 
consisted in the purification of liver progenitor cells from mouse embryos, genetic 
manipulation of the cells ex vivo, followed by their transplantation into recipient mice 
(Figure 3.1). Hepatoblasts were isolated from the fetal liver taken from C57BL/6 
embryos on embryonic day (E) 14.5-18.5 by immuno-affinity purification on 
magnetic beads with an antibody against E-cadherin, a marker of liver hepatoblasts 
(Nitou et al., 2002). Purified cells were cultured on laminin-coated plates for 48hrs in 
a chemically defined medium supplemented with hepatocyte growth factor (HGF), 
epidermal growth factor (EGF) and dexametasone. Following in vitro expansion, 
hepatoblasts were transduced with different combinations of retroviruses expressing 
c-myc, an shRNA targeting p53, or oncogenic Ras (H-RasV12), each of which affects 
signaling pathways altered in human liver cancer. As expected, p53-deficient E14.5 
hepatoblasts transduced with a retrovirus encoding c-myc rapidly acquire an immortal 
phenotype in culture and become transformed, as shown by their ability to generate 
tumors when injected subcutaneously. Moreover, when the same cells are harvested 
and manipulated at a later stage (E18.5), c-myc immortalizes, but does not transform 
them (Zender et al., 2005). Genetically modified cells were injected subcutaneously 
into immunocompromised CD-1 nude mice. Animals were monitored for signs of 
disease and tumor size was measured using a caliper. After 14 days from the 
injection, tumors were harvested and processed for histological analysis.  
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An experienced mouse-pathologist examined several tumor sections stained with 
hematoxylin and eosin (H&E) and confirmed their liver origin. Tumors were 
classified as pseudoglandular, mixed pseudoglandular tubular, or mixed solid 
trabecular each resembling a typical growth pattern of human HCC (Zender et al., 
2005)(Fig. 3.2). In addition, tumors were stained with liver-specific markers: albumin 
(differentiated liver cells), α-fetoprotein (fetal-specific glycoprotein, expressed in 
tumors), cytokeratin 19 (marker of biliary differentiation) conforming their identity as 
liver tumor (Fig. 3.3). Thus, as observed by Zender et al (2005), tumors arising from 
ex vivo manipulated liver progenitor cells exhibited features of human HCC, 
providing a valid experimental system to investigate the role of oncogenic and tumor 
suppressive events in this tumor model. 
 
 
Figure 3.1: Schematic representation of the general strategy. E-Cadherin-positive 
fetal liver hepatoblasts were purified using an immunomagnetic bead based procedure 
and cultured on laminin-coated plates for two days. Cells were retrovirally transduced 
with c-myc, H-RasV12 and/or an shRNA directed against the tumor suppressor gene 
p53. Upon clonal expansion, cells were injected subcutaneously into recipient mice or 
used for in vitro experiments.  
 




Figure 3.2: H&E of subcutaneous tumors reveal histopathological subtypes of 
human HCC. Histopathological analysis of tumors derived from E14.5 E-Cadherin+ 
liver progenitor cells transduced with different combinations of H-RasV12, Myc and 
shp53. Subcutaneous tumors closely resembled different histological subtypes of 
human HCC, as indicated beside each panel. Magnification is 20x. 
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Figure 3.3: Immunohistochemical staining of subcutaneous HCC-like tumors. 
Tumors were stained for albumin (ALB) and α-fetoprotein (AFP), markers of 
embryonic liver progenitors and HCC, and cytokeratin 19 (CK-19), a marker of bi-
potential liver progenitors. All tumors examined were positive for at least one of these 
markers confirming their liver origin. Magnification is 20x. 
 
3.2 ST18 is poorly expressed in cell lines but highly expressed in tumor 
samples 
 
ST18 is poorly expressed in liver (Jandrig et al. 2004), but a recent profiling of L1 
retro-transposition events in human HCC has led to the proposal that its up-regulation 
may be a tumor-promoting event (Shukla et al., 2013). We thus sought to determine 
whether ST18 is expressed in our mouse tumor model. We used quantitative RT-PCR 
to measure mRNA expression levels of ST18 in in vitro cultured liver progenitors 
cells as well as matched tumor samples derived from subcutaneous injection of the 
same cell population. Genetically modified hepatoblasts, whether immortalized or 
transformed, poorly expressed ST18 (Fig. 3.4-A). Instead, subcutaneous tumors 
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derived from the same transformed cells displayed higher ST18 mRNA levels (Fig. 
3.4-B). We confirmed these results by immunohistochemistry on tumor sections using 
an antibody against the ST18 protein. Indeed, normal liver tissue showed little or no 
ST18 signal while tumors stained positive for ST18 (Fig. 3.5). Moreover, as expected 
for a zinc finger DNA binding protein, we observed a predominantly nuclear staining 




Figure 3.4: mRNA expression analysis of ST18 in cultured cells and tumor tissue. 
Panel A: Quantitative real-time RT-PCR analysis of ST18 expression in immortalized 
hepatoblasts (E18.5 shp53/c-Myc), in transformed hepatoblasts (E14.5 shp53/c-Myc), 
in liver and in two different tumors arising after subcutaneous seeding of transformed 
cells in CD-1 nude mice. Panel B: Quantification of ST18 expressing levels in six 
different cell lines derived from various combinations of H-RasV12, c-Myc and shp53, 
and their corresponding tumors. Despite heterogeneity of expression amongst the 
tumors, the ST18 levels were significantly higher in tumors compared to cultured 
transformed cells.  
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Figure 3.5: Immunohistochemistry for ST18 in tumors and liver tissue. Normal 
adult liver and two different subcutaneous tumors were stained using antibodies 
against ST18 revealing positivity in tumors compare to normal liver. Insets (40x 
magnification) denote the high nuclear positivity in tumors and low signal in normal 
liver tissue. Big panels are shown at magnification of x10. 
 
3.3 ST18 is induced by inflammatory stimuli 
 
The data presented above showed that ST18 expression increases both at the mRNA 
and protein level in tumors, while it is almost undetectable in normal liver tissue. 
ST18 may also regulate pro-inflammatory gene expression in fibroblast (Yang et al., 
2008), pointing to a direct role in the inflammatory response.  
To address a possible link between ST18 expression and inflammation, we induced an 
acute inflammatory response in C57BL/6 mice by intra-peritoneal injection of 
bacterial lipopolysaccharide (LPS) (Zhong et al., 2006)and we sacrificed the mice 24 
hours after injection. Formalin-fixed paraffin-embedded (FFPE) liver sections from 
control and LPS treated mice were stained with hematoxylin/eosin (Fig. 3.6, upper 
panel). As expected (reviewed in (Nesseler et al., 2012), LPS administration causes 
severe hepatic dysfunction and liver damage.  Additionally, as shown in Fig 3.6, ST18 
expression was induced upon LPS treatment, especially nearby blood vessels and bile 
ducts. We conclude that ST18 expression is augmented upon acute liver 
inflammation. 
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Figure 3.6: LPS treatment induces ST18 expression in liver. First row: 
Hematoxylin and eosin staining shows severe hepatic dysfunction and infiltration 
(white arrows) in mouse livers 24 hours post treatment with LPS compared to 
untreated liver. Second row: IHC performed on the same livers samples using an 
antibody against ST18. LPS treated livers showed high positivity for ST18 in the 
vicinity of blood vessels and bile ducts as shown by black arrows, instead in untreated 
liver the expression of ST18 is very low. (10x magnification) 
 
Next, we investigated whether upregulation of ST18 also occurs in chronically 
inflamed livers. It has been shown that the ST18 locus is frequently amplified in HCC 
nodules from the Mdr2−/− mouse model of inflammation-driven HCC (Shukla et al 
2013). These mice lack the P-glycoprotein of the bile canaliculi membrane of 
hepatocytes, and as a consequence lack lipid secretion, show persistent damage of the 
biliary epithelium - induced by high concentration of monomeric bile salts - and a 
chronic inflammatory response (Fickert et al., 2004; Mauad et al., 1994). Mdr2-/- 
mice have an age-dependent progressive deregulation of genes that lead to 
development of pre-neoplastic lesions and liver dysplasia within the first 10 months 
of age followed by the development of HCC (Katzenellenbogen et al., 2007).  
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We decided to verify the expression of ST18 protein in FFPE liver sections from 
pretumoral Mdr2-/- mice. Sections of inflamed, pre-neoplastic livers obtained from 
Mdr2-/- mice at the age 4-10 months were stained with an antibody against ST18. 
Liver from control mice showed a weak staining while Mdr2-/- livers were positive 
for ST18 (Figure 3.7). We thus confirmed that ST18 expression correlates with 
chronic liver inflammation in the Mdr2-/- mouse model. 
 
Figure 3.7: Pretumoral inflamed livers from Mdr2 -/- mice express ST18. IHC 
with anti-ST18 in Mdr2 wt liver and in two different Mdr2-/- livers showing that 
pretumoral inflamed Mdr2-/- livers were highly positive for ST18 compared to the 
low expression in normal liver tissue. 
 
Despite minor differences between murine and human disease, HCC lesions 
developed by Mdr2-/- mice share a very close tumorigenic process with those 
observed in a chronic inflammatory setting in pediatric patients with progressive 
familial intrahepatic cholestasis 2 (PFIC2). As detailed in the Introduction (see 
section 1.7), these patients have a mutation in the ABCB11 gene, which encodes a 
membrane transporter required for the export of bile salts from hepatocytes, leading to 
chronic inflammation and to HCC (Knisely et al., 2006). In order to investigate 
whether ST18 might also be up-regulated in individuals with PFIC2 mutations, we 
performed immunohistochemical analysis using an antibody against ST18 on FFPE 
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sections from liver biopsies from these patients as well as from livers affected by 
cirrhosis, to distinguish between neoplastic cells and cirrhotic surrounding tissue. 
Normal liver tissue and cirrhotic tissue showed low ST18 expression, while PFIC2 
livers were strongly positive for ST18 (Fig 3.8). Hence, deficiency of the membrane 
transporter genes Mdr2 and ABCB11 led to analogous effects in mice and humans, 
respectively, with chronic inflammation and induction of ST18 expression. 
We therefore hypothesized that expression of ST18 in tumors might be the result of 
an upregulation of inflammatory pathways during tumor development.  
 
 
Figure 3.8: Patients with PFIC2 express ST18 in the liver. IHC analysis of ST18 in 
normal liver and in three different PFIC2 patient liver biopsies and in cirrhotic liver 
samples. Livers from patients with PFIC2 were highly positive comparing the low 








	   43	  
3.4 Ectopic expression of ST18 is toxic to hepatoblasts in vitro  
 
To uncover the effect of the ectopic expression of ST18, we performed in vitro GFP 
competition assay using either E14.5 hepatoblasts (previously transformed with c-
myc/shp53/H-RasV12 (see section 3.1) or NIH/3T3 fibroblasts. Both cell types were 
transduced at low multiplicity of infection (MOI) with a GFP-tagged retroviral vector 
expressing human ST18 (MSCV-ST18-FLAG-IRES-GFP) in order to obtain an 
infection efficiency of ~35%. Expression of the tagged ST18 protein was confirmed 
by immunoblotting, with similar levels in both cell types achieved 24h after infection 
(Fig. 3.9). Monitoring the levels of GFP-positive cells showed a progressive reduction 
in ST18-expressing cells over the initial passages, which did not occur in cells 
infected with the corresponding empty vector (MSCV-IRES-GFP) (Figure 3.10 A, B). 
It is noteworthy that GFP expression levels obtained by the transduction of cells with 
the vector containing ST18 are lower than those with empty vector, albeit 
reproducibly above background fluorescence in uninfected cells. Moreover, the same 
effect is apparent in the immunoblots shown in Figure 3.9. In the case of the 
hepatoblasts, the counter-selection of ST18-expressing cells was confirmed in six 
independent experiments (Fig. 3.11). In populations infected with the ST18-
expressing vector, GFP-positive cells showed clear morphological changes, in 
particular a large flat morphology reminiscent of the activation of a senescence 
program (Fig. 3.12-A, B). While the cellular and molecular mechanisms associated 
with this effect remain to be characterized in detail, our data show that ectopic 
expression of ST18 in either hepatoblast or fibroblast in vitro is toxic to the cells.  
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Figure 3.9: Immunoblot analysis in NIH/3T3 and hepatoblasts. Immunoblot 
analysis of FLAG-tagged ST18 in NIH/3T3 fibroblasts (48h after infection) and in 
transformed hepatoblasts (E14.5 c-myc/shp53/H-RasV12) at 24/48h. The efficiency of 
ST18 knockdown is also shown. ST18 knockdown is visible as a decrease of FLAG 
and GFP expression in cells coinfected with overexpression and silencing plasmids. 
The silencing of ST18 was used for further experiments (see below). Vinculin was 
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Figure 3.10: ST18/GFP+ expressing hepatoblasts and NIH/3T3 are 
counterselected. Flow cytometric analysis of single-cell suspensions prepared from 
transformed hepatoblasts (E14.5 c-myc/shp53/H-RasV12) (panel A) or NIH/3T3 (panel 
B) following infection with empty vector (EV, MSCV-IRES-GFP) or with MSCV-
ST18-FLAG-IRES-GFP. Whilst, cells infected with EV maintained stable percentage 
of GFP+ cells over several passages, ST18-GFP expression in hepatoblasts or 
fibroblasts decreased over time. Insets give the percentages of GFP positivity 
normalized to the first day considered 100%. Blue columns (EV) remain constant and 
red columns (overexpression of ST18) decrease during the course of the experiment.  
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Figure 3.11: The ectopic expression of ST18 in hepatoblasts is cytotoxic as GFP-
positive cells are counterselected. Chart summarizing flow cytometric analysis of 
GFP profiles seen in six independent experiments (A-F). Hepatoblasts infected with 
MSCV-ST18-FLAG-IRES-GFP lose GFP positivity over time whereas cells infected 
with EV (MSCV-IRES-GFP) remain GFP-positive. Analysis of variance (ANOVA) 
showed that the two groups are significantly different, P value of 1.4e-6 ***. 
 
	   47	  
 
 
Figure 3.12: Morphological changes upon ST18 overexpression in hepatoblast 
and NIH. Overexpression of ST18 (here shown indirectly by observing GFP+ cells) 
leads to morphological changes (large flat shape) both in transformed hepatoblasts 
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3.5 Conditional expression of ST18 in CRE-ERT2  hepatoblasts 
 
As ectopic expression of ST18 in vitro led to impaired hepatoblast proliferation, and 
as the in vivo model system used here requires initial transduction of hepatoblasts ex 
vivo, we decided to set up a conditional expression system that would allow us to 
induce expression of ST18 directly in tumors following transplantation. We thus 
derived E14.5 hepatoblasts from heterozygous CRE-ERT2 embryos, transduced these 
cells with the transforming constructs (c-myc/shp53/H-RasV12: see 3.1.) and 
subsequently with a vector allowing conditional expression of ST18 under the control 
of Cre recombinase (MSCV-LSL-ST18-FLAG).  This vector included a dsRed 
expression cassette flanked by LoxP sites inserted upstream of the VENUS-ST18 
coding sequence, thus blocking translation of ST18. The deletion of dsRed by Cre 
recombinase results in the rapid loss of the red marker accompanied by the activation 
of ST18 expression (Fig. 3.13). 
 
Figure 3.13: MSCV-LSL-ST18-FLAG map and primers. The conditional 
overexpression vector for ST18 includes a dsRED cassette flanked by LoxP sites that 
once deleted by Cre-recombination leads to the expression of ST18. The blue arrows 
show the positions of the primers used to determine a successful recombination that 
was seen as a disappearance of a 1000bp band replaced by a 250bp band following 
Cre-recombination. 
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 As described above, constitutive ST18 overexpression led to clear morphological 
changes (see Fig. 3.12), in particular a large flat morphology. On the contrary, the 
treatment of cells infected with the conditional vector with 4-hyydroxy-tamoxifen 
(OHT) to activate CRE-ERT2, did not induce any morphological changes (Fig. 3.14). 
In a parallel experiment, a recombinant TAT-CRE protein was added instead of OHT 
into the culture medium (Fig. 3.14). This treatment let to a rapid increase in GFP 
expression in all hepatoblasts (Data not shown) followed at 48h by the appearance of 
cells displaying large flat morphology and induction of massive mortality similarly to 
the phenotype seen in hepatoblasts transduced with the constitutive ST18 (Fig. 3.14). 
These data indicate that the heterozygous CRE-ERT2 transgene was insufficient to 
induce efficient recombination of the integrated MSCV-LSL-ST18-FLAG provirus, 
while TAT-Cre was, inducing effective expression of ST18 and the concurrent 
cellular arrest. To verify this prediction, we designed two PCR primers, the forward 
on the MSCV plasmid, before the dsRed cassette flanked by LoxP sites, and the 
reverse in the ST18 coding sequence (Fig. 3.13). We performed a PCR reaction on 
transformed CRE-ERT2 hepatoblasts transduced with the MSCV-LSL-ST18-FLAG 
treated or not with OHT. In untreated hepatoblast a 1000bp band (corresponding to 
the un-recombined vector) was aplified, whereas after 72 and 120 hours of OHT 
treatment both 1000 and 250 bp bands were seen. We, thus, concluded that only a 
small percentage of cells was able to recombine RERT (Fig 3.15). Hepatoblasts 
transduced with EV with or without OHT show any PCR bands, as expected from the 
primers design (Fig.3.13 and 3.15).  
We conclude that CRE-ER mediated deletion efficiency was not sufficient for further 
in vivo experiments and that TAT-Cre was much more efficient. We are currently 
deriving hepatoblasts from homozygous CreERT2 embryos in order to achieve 
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effective recombination, an essential condition to address the effects of ST18 
activation on tumor progression in vivo. 
 
  
Figure 3.14: Conditional expression of ST18 in vitro. CRE-ER +/- transformed 
hepatoblasts infected with conditional expression of ST18, after activation with OHT 
or TAT CRE. OHT seems to be unable to activate the overexpression, instead cells 





Figure 3.15: PCR to verify the efficiency of Cre recombination. PCR shows only a 
partial recombination of MSCV-LSL-ST18-FLAG conditional vector upon treatment 
with OHT at the indicated times. Upper band 1000bp show no recombination, lower 
band 250 bp show the recombined vector. Only partial recombination upon OHT 
treatment is visible after 72 and 120h, as the upper band does not completely 
disappear as expected. 
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3.6 ST18 overexpression does not substitute for RAS in oncogenic 
transformation of hepatoblasts 
 
As outlined in section 3.1, we used liver hepatoblasts to assess the transforming 
activity of ST18. We wanted to determine whether ST18 could act as an oncogene by 
transforming in vivo-derived embryonic hepatoblasts. Simultaneous expression of c-
Myc and shp53 in hepatoblasts isolated from fetal livers of embryonic day E18.5 
leads to immortalization of cells that can be propagated in vitro (Zender et al., 2005). 
These cells provide a sensitized background where expressing additional oncogenes 
might trigger transformation and therefore tumorigenesis. As proof of concept, we 
have transduced E18.5 hepatoblasts, previously coinfected with c-myc and an shRNA 
targeting p53, with the oncogenic mutant form of Ras (H-RasV12). As expected, mice 
injected subcutaneously with E18.5 c-myc/shp53/H-RasV12 liver progenitors 
developed tumors within two weeks, while E18.5 c-myc/shp53 cells did not give rise 
to any tumors (mice were monitored for six weeks). We also performed an in vitro 
colony formation assay, culturing E18.5 c-myc/shp53/H-RasV12 cells in a semisolid 
methylcellulose-based medium: two weeks after plating, colonies were only visible in 
the E18.5 c-myc/shp53/H-RasV12 transformed cells (data not shown). To determine 
whether ST18 could phenocopy the results observed with oncogenic Ras in this 
context, we transduced E18.5 c-myc/shp53 immortalized cells with a retroviral vector 
expressing ST18 (MSCV-ST18-FLAG). We injected a cohort of mice subcutaneously 
with E18.5 c-myc/shp53/ST18 cells as well as with E18.5 c-myc/shp53 control cells. 
Neither control, nor ST18 expressing cells gave rise to tumors in vivo, suggesting that 
over-expression of ST18 is not sufficient to cause HCC in cooperation with c-Myc 
and shp53. This conclusion, however, is hampered by the observation that ST18 
overexpression was toxic to the in vitro cultured hepatoblasts, as described in the 
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following section. Conclusive assessment of ST18' s oncogenic potential awaits 
completion of the inducible expression system, as described in the previous section. 
 
3.7 Expression of ST18 is required for tumor development and 
maintenance in vivo  
 
Recently, Shukla et al. identified ST18 as a candidate oncogene activated by L1 retro-
transposition in human HCC (Shukla et al., 2013). As described above, ST18 is not 
expressed in transformed hepatoblasts in vitro, but induced upon tumor development 
in vivo (Fig. 3.4-5): we thus sought to address the consequences of ST18 silencing on 
tumor development. Toward this aim, we first designed a series of shRNA hairpins 
targeting both human and mouse ST18 and initially tested their silencing efficacy by 
western blot in transiently transfected cells (Fig. 3.16). To this end, 293T cells were 
co-transfected with an expression vector containing human ST18 (MSCV-ST18-
FLAG), and several silencing vectors containing single shRNA against ST18, cloned 
into the MLP vector. Among the several shRNAs tested, we selected three of them 
(No 1, 6 and 7, Fig 3.16) showing the highest efficiency of knockdown. 
   
Figure 3.16: Immunoblot analysis to verify the efficiency of ST18 knockdown. 
Immunoblot analysis of exogenously expressed human ST18 in 293T cells co-
transfected with MSCV-ST18-FLAG and several shST18 (single hairpins or as pool). 
After 48h of transfection the hairpin shST18-6 has the highest silencing efficiency.  
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To functionally investigate the consequences of ST18 silencing in vivo, we cloned the 
three functional shRNAs against ST18 (No 1, 6 and 7) into a tetracycline-inducible 
vector that also expresses VENUS (TtRMPVIR, Zuber et al. 2011). We isolated 
hepatoblasts from E18.5 p53-/- embryos, infected them with retroviruses encoding c-
myc and H-RASV12, and further infected this stable population of transformed 
hepatoblast with the conditional shRNAs against ST18. For initial experiments, we 
used shRNA.6, which showed the highest knockdown efficiency. Cells infected with 
TET-on shST18.6 or the control shREN.713 were FACS-sorted to isolate VENUS 
positive cells, allowing us to obtain a population homogeneously transduced with the 
shRNAs vector (Fig 3.17).  
 
 
Figure 3.17: FACS-sorted analysis for Venus tag. Flow cytometric analysis of a 
single-cell suspension prepared from transformed hepatoblasts (E.18.5 p53-/-/c-
Myc/H-RASv12) infected with inducible shST18.6 or shREN.713 after cell-sorting for 
Venus tag.  
 
Purified cells infected with either shST18 or shREN.713 were injected 
subcutaneously into CD-1 nude mice, and the animals were monitored daily for the 
appearance of tumors (Fig. 3.18). Once the tumors were palpable (day 15) we divided 
mice into two groups: one group was fed with doxycycline-containing food to induce 
the activation of the shRNA, while the control cohort was fed with regular food. 
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Another cohort of mice was fed on doxycycline-containing food from the day of 




Figure 3.18: Schematic representation of the general strategy for knockdown of 
ST18 in vivo. Transformed hepatoblasts were infected with an inducible shST18.6 
vector that expresses Venus-GFP constitutively. We injected these cells 
subcutaneously into CD-1 nude mice and provided them doxycycline-containing 
food, which activate the shRNA, at different time points from the day of injection 
(d0) or after tumor onset (d15). 
 
Induction of ST18 knockdown on the day of cell injection caused a significant delay 
of two weeks in tumor development. Moreover, mice treated with doxycycline (active 
shST18) developed smaller tumors, as compared to either untreated mice (shST18 
off) or mice infected with the control vector (shREN.713), with or without 
doxycycline treatment (Fig. 3.19 and 3.20). At the end of the experiment, tumors 
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expressing shST18 from day 0 were five times smaller than those not expressing it. 





Figure 3.19: Visible differences in tumor formation after ST18 silencing from the 
day of injection. Photographs of three different mice per experimental condition. Top 
panel: uninduced (in the absence of doxycycline), , and – bottom panel – induced by 
doxycycline-containing food from the day of injection silencing with shREN.713 or 
shST18.6 from day 0. Mice with tumors arising from activated shST18 bear very 
small growths compared to the non-induced and induced shREN.713.  
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Figure 3.20: Differences in tumor volumes after ST18 silencing from the day of 
injection. Boxplots of subcutaneous tumor volumes derived from transformed 
hepatoblasts infected with shST18 or shREN.713 after three weeks from injection. 
Tumors arising from activated shST18 have very small tumor volumes compared to 
the non-induced tumors (shST18 off). The observations are not due to effects of 
doxycycline per se but due to induction of the shST18 because shREN.713 induction 
shows no phenotype.  
 
The same experiment included a third cohort of mice in which KD of ST18 was 
induced in already established tumors. For this purpose, we let the tumors grow for 
two weeks before switching to doxycycline-containing food, thereby activating the 
shRNA. Two days after the exposure to doxycycline we observed a dramatic change 
in ST18 knockdown (KD) tumor morphology, with multiple edematous and 
hemorrhagic areas (Fig.3.21-A and B), while control tumors arising from shREN.713-
infected hepatoblasts did not show any obvious alterations. To characterize the 
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phenotypic changes at the histological level, formalin-fixed paraffin-embedded 
sections were stained with hematoxilin/eosin and evaluated by a mouse pathologist. 
Widespread necrotic and hemorrhagic areas were observed in tumors with induced 
shST18, but absent in control shREN.713 tumors (Fig.3.22). 
 
 
Figure 3.21: Tumor alterations in tumors upon ST18 knockdown after two days 
from induction. Photographs of mice after 15 days from injection of transformed 
hepatoblasts infected with shST18 or shREN.713. Tumor alterations, in the form of 
hemorrhagic areas, were visible after induction with doxycycline for 2 days and were 
seen only in tumors expressing shST18 whilst tumors expressing shREN.713 were 
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Figure 3.22: Hemorrhages and necrosis caused by silencing of ST18 in tumors. 
Hematoxilin/eosin staining of tumors after shRNA induction by doxycycline-
treatment. Samples of shREN.713 expression tumors were comparable between 
induced and uninduced interference in tumors. Instead, shST18 induction in tumors 
led to high levels of hemorrhages and necrosis.  
 
We then stained for markers of proliferation (Ki67) and apoptosis (Caspase3). 
Tumors with no induction of shST18 were positive for Ki67 and showed no caspase3 
signal, whereas those with active shST18 progressively lost Ki67, accompanied by an 
increase in cleaved caspase 3 (Fig 3.23). Taken together these results indicate that 
knockdown of ST18 in established tumors leads to decreased cell proliferation, 
accompanied by increased apoptotis and visible hemorrhages.  
	   59	  
 
Figure 3.23: Increase in apoptosis and decrease in proliferation in tumors upon 
ST18 knockdown. IHC of subcutaneous tumors with activated/inactivated shST18 
using antibodies against Ki67 (left panel) and caspase3 (right panel). Ki67 staining in 
shST18 tumors resulted in progressive decrease of signal since the day of induction, 
whereas the apoptotic signal increased over time. Insets denote the higher 
magnification view (20x versus 10x).  
 
To confirm that the expression of ST18 is required for tumor maintenance in vivo and 
to exclude possible off-target effects we repeated the same experiment with three 
different shRNAs targeting ST18 (No 1, 6 and 7, Fig.3.16) and induced ST18 
knockdown in established tumors for shorter time-periods (4, 8, 12 and 24h). 
Moreveor, to maximize the activation of shST18, doxycycline was administered by 
oral gavage. At 4 hours, hemorragic areas were already appearing nearby the tumors 
with induced shST18 and after 24h of treatment, the tumor had a clearly altered 
structure compare to the control (Fig. 3.24-A). A repeat of this experiment with 
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shST18.7 showed that hemorrhage occurred as rapidly as 2 hours following 
doxycycline treatment (Figure 3.24-B). 
 
 
Figure 3.24: Tumor alterations are visible in mice upon ST18 silencing. 
Photographs of mice with subcutaneous tumors arisen from transformed hepatoblasts 
infected with shST18 or shREN.713. Panel A show mice before treatment with 
Doxycycline and after 4, 12, 24 hours of induction of the shST18.6 hairpin. Panel B 
show hemorrhages in shST18 mice after 2, 4, 8 hours of induction obtained by the 
induction of shST18.7 hairpin. Tumors derived from transformed hepatoblast infected 
with shREN.713, whether treated or not with doxycycline, show no macroscopical 
alterations.  
 
To confirm that these rapid phenotypic changes could possibly be due to the depletion 
of ST18, we measured mRNA levels by RT-PCR, confirming the rapid and 
significant knockdown of the ST18 mRNA, already apparent after 4 and progressing 
further until 24 hours (Fig. 3.25). A similar picture emerged by immunohistochemical 
analysis with ST18-specific antibodies, demonstrating a general decrease in 
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expression of ST18 (Fig. 3.26). In particular, the expression of ST18 was seen in non-
necrotic areas after 12 and 24 hours post induction. This piece of evidence let us 
hypothesize that ST18 silencing leads to cell death. (Fig. 3.26).  
 
 
Figure 3.25: Efficiency of ST18 knockdown in tumors. Quantitative RT-PCR 
analysis of mRNA levels of ST18 in tumors arisen from transformed hepatoblast 
infected with shST18 N.6, kept untreated or treated with doxycycline after 4, 8, 12, 24 
hours. The efficiency of knockdown in tumors already after 4hours was clear, and 











Figure 3.26: ST18 protein decrease in shST18 tumors after doxycycline 
treatment. IHC for ST18 expression of subcutaneous tumors untreated and after 4, 8, 
12, 24 hours of induction with doxycycline. 10x images were taken to demonstrate the 
differences between tumors. The first column shows ST18 expression tumors before 
the  induction of shRNAs. The first row includes tumors from transformed 
hepatoblasts infected with shREN.713, thus, ST18 is detectable at all time points. 
Instead, the staining for ST18 in shST18 activated tumors, progressively decreases 
post induction. The expression of ST18 at late time-points is present only in the non-
necrotic areas (black arrows). 
 
To describe the morphological changes induced upon ST18 knockdown, formalin-
fixed paraffin-embedded sections were stained with hematoxylin/eosin (Fig 3.27) and 
evaluated by an experienced mouse pathologist (Camilla Recordati) with the 
following diagnosis: In untreated mice (NO Doxy), the subcutaneous mass was 
composed of solid sheets of atypical cells. Atypical cells were polygonal to 
pleomorphic, 20-30 µm in diameter, with indistinct cell borders (highly cohesive). 
Cells had moderate nucleus to cytoplasm (N/C) ratios with moderate amount of 
eosinophilic granular cytoplasm and round vesicular nuclei with 1-3 distinct 
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eosinophilic nucleoli per cell. Occasionally, and mainly located in the centre of the 
mass, few areas of necrosis and hemorrhages were found. Morphologically, the mass 
was consistent with a poorly differentiated tumor, most likely of epithelial origin. In 
shST18 expressing tumors (+ DOXY), multifocal to coalescing moderate to severe 
intratumoral hemorrhages and necrotic areas appeared after doxycycline treatment, 
and increased over time (from 4h to 24h after treatment). The severity of 
hemorrhages and necrosis was variable depending on the shST18 hairpin (6 >> 7 > 
1). Importantly, the histological description and the severity of bleeding and necrosis 
correlated with the knockdown efficiency assayed in 293T cells (Fig 3.16), but to 
sustain this relationship also in tumors ST18 RT-PCR data with all hairpins are still 
missing. Over time, in ST18 KD tumors atypical cells were multifocally less cohesive, 
arranged in bundles, and spindle-shaped, suggesting an epithelial to mesenchymal 
transition (EMT). Overall, atypical cells were moderate, 30-40 micron in diameter, 
with lower N/C ratio, and more abundant eosinophilic granular cytoplasm compared 
to those in untreated mice. Tumors arising from transformed hepatoblast infected with 
shREN.713 had the same morphology of shST18 untreated tumors, and after 
doxycycline treatment maintained solid phenotype with highly cohesive cells (Fig. 
3.27).  
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Figure 3.27: Hemorrhages and necrosis in tumors after few hours of ST18 KD. 
Hematoxilin/eosin staining of tumors with inactive (NO DOXY) or active (+ DOXY) 
shST18 or shREN.713 after 4, 8, 12, 24 hours. Hemorrhages and necrosis with 
progressively strong phenotypes were present in all three shRNAs against ST18 but 
not in the control shREN.713.  
 
We hypothesized that the hemorrhages seen in tumors upon ST18 knockdown were 
linked to alterations in the tumor vasculature. Therefore, we stained these tumors for 
VE-cadherin, a marker of vascular endothelial cells (Giannotta 2013) (Fig. 3.28). The 
structure of the vessels appeared normal, but after 4 hours of doxycycline exposure 
intratumoral blood vessels in ST18 KD tumors were dilated and larger (ectasia) 
compared to untreated mice (Fig 3.28). At the moment, the mechanisms by which 
ST18 elimination leads to this vascular phenotype remain to be clarified, and several 
hypotheses appear plausible. One such theory is that this phenotype might be a direct 
consequence of a specific signaling pathway activated only upon loss of ST18 
expression. Alternatively, tumor necrosis might indirectly lead to alteration of the 
tumor vasculature. 
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Figure 3.28: Vascular alterations are induced in tumors after ST18 silencing. 
IHC for VE-cadherin of shREN.713 and shST18 subcutaneous tumors uninduced (No 
doxy) or induced for 4, 8, 12, 24 hours (+ doxy). Blood vessels in shST18 induced 
tumors appear dilated (see arrows) after 8 hours of treatment.  
 
 
In previous experiments (Fig. 3.24) we had observed a decrease in proliferation and 
the induction of apoptosis after longer periods of shST18 induction. To determine 
how quickly those changes occur, we stained for Ki67 and cleaved caspase3 at early 
time-points (Fig. 3.29 and 3.30). In untreated tumors arising from hepatoblasts 
infected with shST18 or with shREN.713 we detected a strong positivity for Ki67. 
Tumors derived from shREN.713-infected hepatoblasts maintained a high 
proliferative index during the time-course of doxycycline treatment. Instead tumors 
with activated shST18 showed a progressive decrease in Ki67 from 8 to 24 hours, 
indicative of a proliferative arrest (Fig 3.29).  
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Figure 3.29: Silencing of ST18 in tumors leads to decrease in proliferation. IHC 
against Ki67 of shREN.713 and shST18 subcutaneous tumors uninduced (No doxy) 
or induced for 4, 8, 12, 24 hours (+ doxy). Images (10x magnification) show in the 
first column untreated samples with strong positivity for Ki67 underlying high 
proliferation. In the first row, tumors arising from transformed hepatoblasts infected 
with shREN.713 do not show any alteration in proliferation during treatment with 
doxycycline. Instead in tumors with shST18, a progressive decrease in Ki67 signal is 
visible over time.  
 
Caspase3 staining increased in the samples with activated shST18, with variable 
kinetics (Fig. 3.30). Tumors derived from hepatoblast infected with shST18.6, which 
in 293T cells resulted in the highest knockdown efficiency (Fig. 3.16), displayed 
positive caspase3 staining already after 4 hours of treatment, whereas the tumors 
arising from the others two shRNAs against ST18 (No 1 and 7) showed high level of 
caspase3 staining after 24 hours and very low signal after 8 and 12 hours of 
activation. Control tumors arising from shREN.713-infected hepatoblasts were 
negative for caspase3 even after doxycycline treatment (Fig. 3.30). Altogether, we 
conclude that the silencing of ST18 leads to concomitant proliferative arrest and 
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induction of apoptosis: the relationship between these effects remains to be addressed 
in further detail. 
 
Figure 3.30: Silencing of ST18 in tumors leads to an increase in apoptosis. IHC 
against caspase3 of shREN.713 and shST18 subcutaneous tumors uninduced (No 
doxy) or induced for 4, 8, 12, 24 hours (+ doxy). Low magnification (4x) images were 
taken to demonstrate the difference between tumors. Untreated tumors (first column) 
and tumors derived from transformed hepatoblasts infected with shREN.713 (first 
row) are negative for caspase3. Instead in tumors with shST18, a progressive increase 
in caspase3 signal is visible during the hours of activation.  
 
 
We further verified the morphological alterations within the tumors when upon 
induction of shST18 for longer periods. As observed previously, four hours after 
silencing ST18, intratumoral and peritumoral hemorrhages extending to the adjacent 
subcutis were readily noticeable. These hemorrhages became progressively more 
severe over time, causing extensive red discoloration of the whole ventral aspect of 
the mouse after 2 days (Fig. 3.31). At this point we dissected some mice to observe 
the changes in the tumor and to understand the origin of the hemorrhages. The masses 
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were hemorrhagic and friable, difficult to collect for histological examination and no 
gross lesions were found involving the internal organs, indicating that hemorrhages 
were restricted to the tumor and adjacent subcutis (Fig. 3.32). In animals maintained 
further on doxycycline-containing food, the ventral subcutaneous hemorrhages were 
almost completely resolved after 4 days and fluid filled masses were present. 
However, one week after ST18 silencing, some escapers start to proliferate again 
leading to new tumor formation (Fig.3.31). Pathological analyses are ongoing to 
verify the nature of the residual tissue after one week of treatment and additional 
staining will be necessary (first of all ST18) to understand the molecular changes 




Figure 3.31: Long term analysis of tumors following ST18 silencing. Photographs 
of mice with subcutaneous shST18 tumors untreated and treated with doxycycline for 
4 hours and 2, 4, 7 days. Hemorrhages are visible after 4 hours of treatment and 
became detectable in the whole body of the mice after two days. Mice after four days 
of doxycycline absorbed the hemorrhages before start to proliferate again. 
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Figure 3.32: Severe hemorrhages in tumor upon ST18 knockdown.  
High levels of hemorrhages were present and restricted to the tumor and adjacent 
subcutis in ST18 silenced tumors after 2 days of doxycycline compared to tumors 
arisen from shREN.713. 
 
 
Taken together, our in vivo data clearly underline the requirement for ST18 during 
tumor development and progression of murine HCC. Pathological analysis revealed 
ST18 to be a gene that is necessary for the maintenance of the epithelial origin of the 
tumor. Additional stainings are ongoing to confirm the occurrence of epithelial-to-
mesenchymal transition after doxycycline treatment.  
 
3.8 ST18 inhibits genes involved in epithelial to mesenchymal transition  
 
To understand what genes and pathways are involved and regulated by the 
inactivation of ST18 we performed RNA-seq analyses in control tumors and ST18 
KD tumors treated for 4 hours with Doxycycline (three different tumors each, all 
derived from hepatoblasts infected with shST18.6). Expression values for the roughly 
22.000 mouse genes were compared between the two conditions: using a significance 
value (p-value adjusted with Benjamini-Hochberg correction for multiple testing) of 
less then 0.05, we detected 1,690 differentially expressed genes (DEGs). Then we 
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divided them in UP and DOWN regulated genes using the log2 Fold Change (log2FC) 
of the expression ration between the control and the ST18KD samples. We identified 
677 UP (Table S1) regulated genes as those ones that have a log2FC > 0.5, and 467 
DOWN (Table S2) regulated genes with a log2FC < -0.5. To compare gene 
expression levels within and between replicates, Reads Per Kilobase per Million of 
mapped reads (RPKM) values for each gene were calculated. Hierarchical clustering 
analysis of gene expression based on RPKM values separated the tumor samples 
according to the two categories: control (noDox) and ST18KD (4hDox) (Fig. 3.33). 
 
 
Figure 3.33: Hierarchical clustering analysis separated the tumors into untreated 
and treated. Clusters based on RPKM gene expression values denote a correlation 
between the six different biological samples by grouping them according to the two 
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To interpret the gene expression data and identify possible molecular mechanisms 
underlying tumor regression upon ST18 inactivation, we used the Gene Set 
Enrichment Analysis (GSEA) software based on the Molecular Signature Database 
(MSigDB), a collection of annotated gene sets. The MSigDB gene sets are divided 
into 7 major collections: c1 positional gene sets, c2 curated gene sets, c3 motif gene 
sets, c4 computational gene sets, c5 GO gene sets, c6 oncogenic signatures and c7 
immunologic signatures. We concentrated our analysis on collection c2 (curated gene 
sets form already published databases in PubMed), yielding 1923/3262 gene sets up-
regulated in control (noDox) samples versus ST18KD (4hDox), of these 1923 just 407 
gene sets were significantly enriched (p value <0,01) showing a positive enriched 
score (+ES). We also detected 1339/3262 gene sets down-regulated in control 
samples versus ST18KD (meaning that these gene sets were up-regulated in ST18KD 
versus control samples), of these 1339 only 301 gene sets were significantly 
downregulated (-ES) in control versus ST18KD samples  with p value <0,01. 
In control samples we found several enriched gene sets correlating with inflammation; 
in particular we found a high correlation between genes enriched in control and genes 
up-regulated in hepatic stellar cells after stimulation with LPS (the Seki gene set) with 
an enrichment score (ES) of +0,62 (Fig. 3.34) (Seki et al., 2007).  This gene set was 
very interesting, considering that we have previously shown that there is a correlation 
between LPS stimulation in vivo and ST18 expression (Fig. 3.6). 
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Figure 3.34 Enrichment plot of upregulated gene set in control tumors. The green 
line in the enrichment profile gives the enrichment score (+0,62 at its summit) for the 
gene set ‘SEKI_INFLAMMATORY_RESPONSE_LPS_UP). The bottom portion of 
the plot shows where the members of the gene set appear in the ranked list of genes. 
The leading edge subset of a gene set is the subset of members that contribute most to 
the ES. In this case the hits (black lines) are in the red profile control samples (No 
Doxy) and the leading edge subset are the set of members that appear in the ranked 
list prior to the peak score. 
 
 
Several gene sets strongly enriched (1339 / 3262 gene sets are downregulated in 
control  versus 4hDox) upon ST18 silencing were highly correlated with genes up-
regulated during epithelial to mesenchymal transition. In particular we found an ES 
for one EMT set (the Anastassiou gene set) of -0,79, this score is the degree to which 
this gene set is overrepresented at the ranked list of genes in the expression dataset 
(Fig 3.35) (Anastassiou et al., 2011). In detail, the following genes contribute to the 
leading-edge subset within this gene set: CRISPLD2, COL1A2, THY1, TNFAIP6, 
COL1A1, COL6A2, ACTA2, COMP, LRRC15, COL5A2, SULF1, CDH11, NOX4, 
OLFML2B, MFAP5, ADAM12, GLT8D2, LOX, ASPN, THBS2, COL11A1, 
POSTN, PRRX1, DCN, LUM, ITGBL1, C1QTNF3 (Fig 3.36). Highlighted in bold 
typeface are 9 known EMT-associated genes coming from the list of upregulated 
“EMT core signature” genes (Taube et al., 2010) and four additional genes 
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(underlined) have also been reported as EMT related (Huang et al., 2013; Jechlinger 




Figure 3.35 Enrichment plot of upregulated geneset in ST18 knockdown tumors. 
The top portion of the plot shows in green the enrichment profile and the enrichment 
score (ES) of -0,79 for this particular gene set. The bottom portion of the plot shows 
where the members of the gene set appear in the ranked list of genes. In this case the 
hits (black line) are in the blue profile (ST18KD - 4h Doxy treated) and the leading 
edge subset are the set of members that appear in the ranked list subsequent to the 
peak score. 
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Figure 3.36: Heatmap of gene sets upregulated in ST18 knockdown tumors. 
Heatmap of genes in the gene set ‘Anastassiou_cancer_mesenchymal_transition’ 
ordered by their position in the ranked list of genes. Genes related with epithelial to 
mesenchymal transition were highly expressed in ST18KD (4h Doxy) tumors 
compared to control. The analysis includes only those genes in the gene set that are 
also in the expression dataset. In this representation, expression values are detected as 
colors, where the range of colors (red, pink, light blue, dark blue) shows the range of 
expression values (high, moderate, low, lowest).  
 
We also analyzed our data with the ingenuity pathway analyzer software (IPA®) that 
correlate RNAseq data with 5 million published individual findings, most of which 
describing relationships between molecules, diseases or biological functions. IPA was 
used to analyze selected sets of genes after ST18 silencing to identify possible altered 
canonical pathways. The most significant one associated with the higher ratio, 
determining high overlap with the genes of our dataset, was the so-called hepatic 
fibrosis pathway; however, there was no evidence of how the genes are up- or down-
regulated in association with this pathway. The overall activation/inhibition states of 
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canonical pathways are predicted based on a Z-score algorithm that is used to 
compare the uploaded dataset with the canonical pathway patterns. It is clear that 
there is a significant and positive association with inflammatory pathways (i.e. IL-8 
and NF-kB) and VEGF signaling, instead Wnt/β-catenin signaling was negative 
associated (Table 3.1). 
Ingenuity Canonical Pathways -log(p-value) Ratio z-score 
Hepatic Fibrosis / Hepatic Stellate 
Cell Activation 
8.72E+00 2.13E-01  
Calcium Signaling 4.69E+00 1.74E-01 0.832 
IL-8 Signaling 2.05E+00 1.31E-01 1.342 
NF-kB Signaling 1.78E+00 1.27E-01 0.853 
Cardiac β-adrenergic Signaling 1.51E+00 1.28E-01 1.265 
Growth Hormone Signaling 1.38E+00 1.45E-01 1 
TGF-β Signaling 1.11E+00 1.26E-01 0.378 
VEGF Signaling 1.61E+00 1.43E-01 1.732 
Wnt/β-catenin Signaling 1.15E+00 1.12E-01 -3.051 
 
Table 3.1: Canonical pathways altered in ST18 knockdown tumors. IPA analysis 
identified many alterations in association between our defined data sets and the 
canonical pathways; in particular, the most significant one was the hepatic fibrosis 
pathway. The ratio indicates the strength of the association; whereas the p-value 




ST18 is a zinc finger protein, but genome-wide chromatin profiling is still missing 
and therefore its target genes are not known. ST18 could function as transcriptional 
activator or repressor since we observed 677 upregulated and 467 downregulated 
genes (padj <0.05, Log2FC>0,5 or <-0,5) after ST18 silencing, albeit these responses 
might be at least partly indirect. This will require the mapping genomic target sites for 
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ST18 by ChIP-seq. As yet, however, ChIP analysis of ST18 has not been performed 
as it will require the characterization of available antibodies, and - if needed - the 
generation of new ones.  
Gene regulation by ST18 may also be indirect, mediated by other transcription 
factors. In order to identify these factors we used the GSEA MSigDB collection C3, a 
collection of motif gene sets based on conserved cis-regulatory motifs from a 
comparative analysis of the mouse genomes. In ST18KD tumors we found up-
regulated 464/797 gene sets within this category (116 with p <0.01). Snapshot of the 
top six enrichment results reveal an enrichment of the transcription factor myocyte 
enhancer factor 2 (MEF2), meaning that differentially expressed genes contain the 
MEFs consensus site within their promoter (Fig. 3.37).  
 
 
Figure 3.37: Snapshot of top results in GSEA motif gene set. Several enrichment 
plots for the gene sets with the highest absolute normalized enrichment scores were 
correlated with the myocyte enhancer factor 2 (MEF2) transcription factors. 
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In vertebrate, the MEF2 family of transcription factors consists of four members (a-
d), and plays a central role in activating genetic programs that control cell 
differentiation, proliferation and morphogenesis (Potthoff and Olson, 2007). All the 
Mef2 family members were expressed in our experimental model, but only Mef2c 
was one of the genes differentially expressed in ST18KD tumors compared to control 
(padj <0.05, Log2FC +1.2). We conclude that upon ST18 silencing, MEF2 activity 
may increase and participate to the biological effects described above. We 
hypothesize that ST18 may repress genes by suppressing MEF2 and we will verify 
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4. DISCUSSION 
 
4.1 Hepatocellular carcinoma: genetic heterogeneity and therapeutic 
targets 
 
Hepatocellular carcinoma (HCC) is the primary form of liver cancer and the third 
greatest cause of cancer-related death worldwide (Llovet et al., 2003). HCC is a 
complex disease, which can have different etiological origins, including infection by 
hepatitis B or C viruses (HBV, HCV), alcohol abuse, or aflatoxin exposure (Gomaa et 
al., 2008). HCC management is further complicated because it is diagnosed mostly at 
advanced stages, when limited therapeutic options are available. HCC is a 
chemoresistant cancer and the only treatments are surgical resection or liver 
transplantation (Llovet and Bruix, 2003). Until recently, patients with advanced HCC 
could only be proposed supportive therapy and care. The advent of Sorafenib, 
approved by the U.S. Food and Drug Administration in 2007, has offered hope to 
patients with advanced HCC (Llovet et al., 2008). Sorafenib is a multi-kinase 
inhibitor that blocks the MAPK pathway, which inhibits the ability of the cell to resist 
apoptosis and decreases angiogenesis, cell migration and proliferation (Llovet et al., 
2008). Despite the successful use of Sorafenib in treatment of HCC, patients with 
advanced tumor still die and there is an urgent need for the development of novel 
targeted methodologies. 
HCC is a heterogeneous tumor with several genetic alterations that can cause p53 
inactivation, Myc over-expression, deregulated Wnt or TGFβ signaling. These genetic 
changes are just a part of the constellation of different types of alterations that lead to 
cancer development and progression: it is therefore clear that combination therapies 
would be critical to overcome the complexity of HCC. The increasing knowledge and 
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the identification of possible HCC driving pathways will provide new therapeutic 
targets. 
 
4.2 The controversial role of ST18 in cancer 
Recently Shukla et al. have shown that insertional mutagenesis mediated by the 
endogenous L1 retrotransposon occurs at the ST18 locus (suppressor of 
tumorigenicity 18) in human HCC pointing to ST18 as candidate oncogene in HCC 
(Shukla et al., 2013). In the same report, other observations support the putative 
oncogenic role of ST18 in liver cancer: (i) clonal amplification of tumor cells with L1 
insertion in ST18; (ii) ST18 expression in tumors and liver cancer cell lines; (iii) ST18 
amplification and expression in inflammation-driven HCC nodules in Mdr2-/- mice 
(Shukla et al., 2013). However, further functional validation of ST18 was achieved 
neither in this paper, nor in a previous report identifying ST18 as a putative oncogene 
in Pediatric Acute Myeloid Leukemia (Steinbach et al., 2006). Other work, instead, 
depicted ST18 as a tumor suppressor in breast cancer (hence the name “Suppressor of 
Tumorigenicity 18”) (Jandrig et al., 2004). ST18 was expressed at low levels in 
mammary epithelial cells and further downregulated in breast cancer cell lines and in 
breast tumors. Moreover, ectopic expression of ST18 in breast cancer cells inhibited 
colony formation in soft agar and tumor formation in xenograft mouse model (Jandrig 
et al., 2004). The tumor suppressor role of ST18 is consistent with its pro-apoptotic 
action, described in human fibroblast (Yang et al., 2008) and in pancreatic β-cells 
(Henry et al., 2014). 
The ST18 gene encodes a zinc-finger DNA-binding protein (Jandrig et al., 2004) with 
similarity to members of the NZF/MyT family of zinc-finger transcription factors 
involved in development and homeostasis of the nervous system (Yee and Yu, 1998). 
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In 1998 a third member of the NZF/MyT family was cloned, neural zinc finger factor 
3 (NZF-3), renamed few years later as ST18 (Yee and Yu, 1998) (Jandrig et al., 
2004). The transient overexpression of ST18 caused spontaneous neuronal induction 
and differentiation in mouse P19 embryonic carcinoma cells, suggesting a central role 
of ST18 in neuronal differentiation (Kameyama et al., 2011). On the other hand, a 
pro-inflammatory role for ST18 was suggested in human fibroblasts, in which ST18 
silencing with small interfering RNA (siRNA) led to the down-regulation of genes 
involved in several inflammatory pathway (including NF-kB, TNF, IL-6) . In the 
same report, overexpression of ST18 significantly increased the expression of TNF-α, 
IL-1α and IL-6, suggesting that ST18 regulates pro-inflammatory gene expression in 
human fibroblast (Yang et al., 2008). In summary, different roles for ST18 have been 
described in several tissues, suggesting that its biological function may be context 
dependent.  
 
4.3 The role of inflammation and micro-environmental signals in 
modulating ST18 function 
Following up from the controversial reports on the role of ST18 in different contexts 
and the recent paper of Shukla et al (2013) that proposed ST18 as a putative oncogene 
in liver cancer, we decided to investigate the role of ST18 during liver tumor onset 
and progression. In accordance with published observations (Jandrig et al., 2004), we 
confirmed that ST18 was expressed at very low levels in normal liver, as well as in 
liver progenitor cells overexpressing a combination of oncogenes (c-Myc and H-
Rasv12) with knockdown of the tumor suppressor p53 (shp53). In matched tumor 
samples derived from subcutaneous injection of the same cells into CD-1 nude mice, 
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we observed an increase of ST18 expression both at the mRNA and protein levels. 
Our results provide direct evidence that simple oncogene activation (or repression of 
tumor suppressors) is not sufficient to induce expression of ST18. Instead, ST18 
expression in vivo requires additional tumor-derived micro-environmental signals, 
likely including cell-cell interactions or soluble factors, such as inflammatory 
mediators or tumor metabolites.  
The tumor environment is a complex mix of tumor cells, tumor-associated cells and 
extracellular matrix components, which creates a system of reciprocal signaling 
(Hernandez-Gea et al., 2013). The interaction between cancer, stromal and 
inflammatory cells creates a network at the basis of a permissive tumor environment 
that favors tumor growth and progression. Stromal cells can be divided into three 
general classes: (i) angiogenic vascular cells, which promote tumor vascularization; 
(ii) cancer-associated fibroblasts, which contribute several tumor-promoting 
functions; (iii) infiltrating immune cells such as macrophages or T lymphocytes, 
whose role in cancer progression is complex and probably depends on context-
specific cues (Hanahan and Coussens, 2012). In this regard, inflammatory infiltrates 
are found in most solid tumors, and cytokines released by innate immune cells, such 
as TNF-a and IL-6, promote tumorigenesis through several mechanisms (Mantovani 
et al., 2008). As mentioned above, the overexpression of ST18 in human fibroblasts 
significantly increased the expression of TNF-α, IL-1α and IL-6 suggesting a 
reciprocal link between ST18 and inflammation (Yang et al., 2008).  
To address a possible link between ST18 expression and inflammation in the liver, we 
induced an acute inflammatory response in C57/B6 mice by intra-peritoneal injection 
of Bacterial lipopolysaccharide (LPS) (Zhong et al., 2006). LPS causes accumulation 
of macrophages and to the release of many inflammatory cytokines including IL1β, 
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TNF-α, TGFβ and IL-6 in the liver, leading to an acute inflammatory response 
(Zhong et al., 2006). Immunohistochemical analyses on livers upon LPS treatment 
showed that ST18 was induced in the inflamed livers suggesting that the gene 
responds acute inflammatory conditions, and thus probably to one or more of the 
cytokines released in these circumstances.  
In accordance with the notion that inflammation and liver tumorigenesis are highly 
interconnected, our RNA-seq analyses on subcutaneous tumors from transformed 
hepatoblasts pointed out an inflammatory gene expression signature. Moreover, based 
on our RNA sequencing data, genes up-regulated in hepatic stellar cells after 
stimulation with LPS (Seki et al., 2007) were expressed in subcutaneous tumors, and 
down regulated after ST18 knockdown. These observations suggest that ST18 
expression in HCC may be induced by inflammatory signals, and that ST18 itself 
regulates part of the transcriptional response induced by those signals. These findings 
may also explain why ST18 is expressed at higher levels in subcutaneous tumors than 
in cell culture, where no inflammatory mediators are present. Different experiments 
are ongoing to mimic this condition of cytokine release in vitro with the aim of 
identifying the factor(s) that lead to induction of ST18. 
In accordance with available data on the expression of ST18 in Mdr2−/− mouse model 
of inflammation-driven HCC (Shukla et al., 2013) we decided to verify if ST18 was 
expressed also in a condition of chronic inflammation. Mdr2−/− mice lack a P-
glycoprotein on the bile canalicular membrane of hepatocytes, causing defective lipid 
secretion. The high concentration of monomeric bile salts causes persistent damage of 
the biliary epithelium, with a consequent inflammatory response, followed by 
development of HCC with a characteristic age-dependent progression from pre-
neoplastic lesions to liver adenoma and finally carcinoma by the age of 12 months 
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(Katzenellenbogen et al., 2007). We demonstrated by immunohistochemistry on 
Mdr2−/− pre-tumoral inflamed livers that ST18 was highly expressed in comparison 
with wt livers, consistent with a possible role of chronic inflammation in modulating 
ST18 expression.  
Mdr2-/- phenocopies a rare human liver disease called progressive familial 
intrahepatic cholestasis type 2 (PFIC2), caused by mutation of the ABCB11 gene 
encoding for a bile salt export pump (Jacquemin, 2012). Mutations in this gene lead to 
bile duct hyper-proliferation and portal fibrosis, and patients often develop 
hepatocellular carcinoma or cholangiocarcinoma (Chan and Vandeberg, 2012). 
Immunohistochemical analysis showed elevated ST18 expression in PFIC2 liver 
tumor biopsies compared to normal human liver, reminiscent of what observed in 
Mdr2-/- mice. It is noteworthy that ST18 was not expressed in the surrounding 
cirrhotic tissue: this is probably due to the nature of cirrhosis, in which liver tissue is 
replaced by non-functioning scar tissue. Thus, Mdr2-/- mice and PFIC2 patients share 
a very similar tumorigenic process derived from a chronic inflammatory setting, 
which could be the reason for ST18 activation. Altogether, the data indicate an 
important role of acute or chronic inflammatory signals in the induction of ST18 
expression in mouse and human livers.  
One of our next experiments will be to test the expression of ST18 in tissue derived 
from patients with two PFIC related diseases, PFIC1 and 3. Unlike PFIC2 these liver 
disorders, stemming from mutation on different hepatocellular transport system genes, 
do not degenerate into hepatocellular carcinoma (Jacquemin, 2012). PFIC3 patients 
carry a mutation in the ortholog of mouse Mdr2 the ABCB4 gene (also called MDR3), 
which encodes for a phospholipid floppase involved in biliary phosphatidylcoholine 
secretion, similarly to Mdr2 (Chan and Vandeberg, 2012). However, unlike Mdr2 
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deletion in mice, this mutation does not lead to cancer development in humans: the 
biological basis for this difference is currently unclear.  
We have demonstrated that ST18 is expressed in subcutaneous tumors and in liver 
under acute and chronic inflammation, however we have not investigated possible 
gene amplifications in these conditions. ST18 amplification was observed in HCC 
nodules in Mdr2-/- mice (Shukla et al., 2013) as well as in tumors from 6/7 patients 
with PFIC2 mutations (Iannelli et al., 2014). Thus, amplification of ST18 - or a 
closely linked gene - was positively selected during tumor development in chronically 
inflamed liver. Considering the correlation between ST18 expression and 
amplification in Mdr2-/- HCC nodules and in PFIC2 liver patient, it remains to be 
addressed whether gene amplification also occurred in the ST18-expressing 
subcutaneous tumors derived from transformed hepatoblasts. Altogether, the above 
observations suggest that inflammatory conditions induce expression of ST18 and that 
further increases in expression, whether occurring through gene amplification, L1 
insertion or other mechanisms, may be positively selected during tumor progression.  
 
4.4 Possible roles of ST18 in liver tumorigenesis 
The expression of ST18 in inflamed livers and HCC in human and mouse samples has 
been extensively discussed in our report. However, the oncogenic potential of ST18 in 
liver proposed by Shukla et al (2014) is still unclear and we tried to determine 
whether ST18 could act as an oncogene by transforming in vivo-derived embryonic 
hepatoblasts. Liver progenitor cells isolated from E18.5 p53-/- embryonic mouse livers 
and infected with retrovirus expressing c-Myc are only immortalized but not 
transformed (Zender et al., 2005). These cells provide a sensitized background where 
expression of additional oncogenes might trigger transformation and therefore 
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tumorigenesis. ST18, unlike H-Rasv12, did not cooperate with c-myc and shp53 to 
induce transformation of immortalized fetal hepatoblasts. Additional experiments 
with different combination of oncogenes and tumor suppressors are needed to verify 
whether ST18 may have oncogenic properties. In addition, pro- or antitumoral 
properties of ST18 may depend on its expression levels. Ectopic expression of ST18 
induced cell death in both hepatoblasts and NIH/3T3, but it remains to be addressed 
whether this was due to over-expression of exogenous ST18 above physiological 
levels (such as those observed for the endogenous protein in inflamed liver or HCC) 
or to a context-dependent effects of ST18. 
Following from the above observations, we studied the role of ST18 in tumor 
development and maintenance in vivo. In particular, we infected a stable population of 
transformed hepatoblasts with conditional shRNAs against ST18 and FACS-sorted the 
cells to obtain a homogeneously transduced population that was then injected 
subcutaneously into CD-1 nude mice. When ST18 knockdown was induced 
immediately upon injection, mice developed smaller tumors compared to control 
mice, as scored two weeks after injection. When ST18 KD was induced in established 
tumors, instead, we observed a dramatic change in tumor morphology, with multiple 
edematous and hemorrhagic areas. Silencing of ST18 in tumor cells led to changes in 
tissue consistence, increase in apoptosis, decrease in proliferation and blood vessel 
alterations. We conclude that ST18 is involved in both tumor development and 
maintenance in liver cancer.  
Pathological analysis of tumor samples after ST18 KD revealed an increased number 
of less cohesive spindle-shaped cells, suggesting that tumor cells had undergone 
epithelial to mesenchymal transition (EMT). EMT is a very complex process in which 
epithelial cells acquire mesenchymal features including loss of cell-cell adhesion, 
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altered polarity and cytoskeletal reorganization (Ogunwobi and Liu, 2012). A 
hallmark of EMT is the loss of epithelial characteristic (e.g., a decrease in E-cadherin) 
and acquisition of mesenchymal markers (such as Vimentin and Twist) (Li et al., 
2013b). For this reason we are planning to perform immunohistochemical stainings to 
verify the expression of EMT-related genes in ST18 KD tumors.  
The aforementioned pathological observations were in agreement with our RNAseq 
analysis on ST18 KD tumors, where several enriched gene sets included EMT-
associated genes. The mesenchymal transition is an established process in embryonic 
development and plays an important role in liver fibrosis (Lee et al., 2014). We 
furthermore observed using the IPA software that many pathways resulted altered 
after ST18 KD; in particular the pathway that was most significant and at the same 
time had highest overlap with the genes in our dataset was the hepatic fibrosis 
pathway, suggesting a change in the nature of ST18 KD tumor cells and confirming a 
possible epithelial to mesenchymal transition (Lee et al., 2014). In summary, ST18 
KD in established tumors leads to morphological changes, whereby epithelial cells 
seem to acquire mesenchymal features as revealed by both pathological and RNAseq 
analysis. 
Mesenchymal cells show enhanced flexibility and motility, at the basis of their 
migratory and metastatic potential (Ogunwobi and Liu, 2012). However the evidence 
that silencing ST18 leads to metastasis was still not addressed in our system. To study 
the metastatic capacity of ST18 KD hepatoblasts, it will probably be necessary to 
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4.5 Possible ST18 mediators preventing the epithelial to mesenchymal 
transition  
 
As we previously described, inflammation has a critical role in tumorigenesis and in 
modulating ST18 expression. Moreover inflammation is a key inducer of EMT, and 
EMT has been linked to both inflammation and cancer (Zhou et al., 2012). As 
described above ST18 seems to prevent the onset of EMT in our tumor model: while 
the mediators of ST18 implicated in this biological effect are still unknown, our 
RNAseq analysis allows us to hypothesize a role for TGFβ signaling and/or for the 
transcription factor MEF2 (myocyte enhancer factor 2). 
TGFβ is an important element in the maintenance of normal tissue homeostasis, in 
which it can either suppress cell proliferation or induce apoptosis, while in cancer 
tissue it can promote tumor progression by inducing EMT and rendering tumors more 
invasive (Giannelli et al., 2014). TGFβ has been shown to induce apoptosis in a 
fraction of cells and to simultaneously induce EMT in other cells within the same 
tumor mass, meaning that cells can respond differentially to the same factor (Song, 
2007). There is also evidence that the cell cycle state and changes in the cellular 
microenvironment are important determinants of whether TGFβ can induce EMT or 
apoptosis (Leight et al., 2012; Song, 2007). Dysregulation of apoptosis and EMT are 
implicated in several pathological events, such as fibrosis of the liver (Song, 2007). 
Moreover TGFβ has a central role in all stages of liver disease from initial injury 
through inflammation, fibrosis and progression to HCC (Giannelli et al., 2014). 
In our RNAseq data, the TGFβ pathway was upregulated after ST18 KD in tumors, 
even though not significantly enriched. While additional experiments are needed to 
dissect the role of TGFβ in ST18 KD, we surmise that the possible inhibition of TGFβ 
by ST18 could have an important clinical relevance (Fig. 4.1). Recent results of phase 
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II clinical trials of TGFβ inhibitors show clinical benefits and reduction of EMT in 
HCC patients (Giannelli et al., 2014).  
To identify possible transcription factors affected by ST18 KD, we analyzed our 
RNA-seq data with the Gene Set Enrichment Analysis (GSEA) software based on the 
Molecular Signature Database (MSigDB). This revealed an enrichment of the 
transcription factor myocyte enhancer factor 2 (MEF2) in the promoters of activated 
genes in ST18 KD tumors samples. MEF2 is a transcription factors family that plays a 
central role in activating genetic programs that control cell differentiation, 
proliferation, morphogenesis, survival and apoptosis (Potthoff and Olson, 2007). 
Recently, MEF2 family members were found to increase during TGFβ1 stimulation, 
further promoting the expression of TGFβ1 in HCC cells (Yu et al., 2014). In the 
same report, the authors concluded that MEF2 promotes EMT and invasiveness 
through this TGFβ1 auto-regulation circuitry (Yu et al., 2014). 
We therefore checked which MEF2 members were expressed in our experimental 
model and we found MEF2c as one of the genes differentially expressed and up-
regulated in ST18 KD tumor. MEF2c is known to be a central regulator of cell 
differentiation and organogenesis (Potthoff and Olson, 2007) and a recent paper 
provides evidence that MEF2c showed double-edged activities in HCC (Bai et al., 
2014): MEF2c inhibited HCC cell proliferation in vitro and in xenograft models by 
impinging on Wnt/β-catenin pathway via blockade of nuclear translocation of β-
catenin, and/or promoted tumor progression by stimulating VEGF. In our RNAseq 
data, the Wnt/β-catenin pathway was inhibited, while the VEGF pathway was 
upregulated after ST18 KD. These data suggest a possible role of ST18 in inhibiting 
MEF2c to prevent EMT and tumor progression (Fig.4.1). Future experiments of 
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conditional silencing of MEF2c in co-operation with silencing of ST18 are needed to 
verify the hypothesis that ST18 inhibits MEF2c.  
 




4.6 Vascular alterations in the tumors after ST18 silencing 
 
Silencing ST18 in established tumors leads to high level of hemorrhages and we 
demonstrated by immunohistochemistry on VE-cadherin, a marker of vascular 
endothelial cells, that intra-tumoral blood vessels were dilated as compared to vessels 
in untreated mice. The mechanisms by which ST18 KD leads to this vascular ectasia 
remain to be clarified, but it might be a direct consequence of a specific signaling 
pathway activated only upon loss of ST18 expression. TGFβ, as we previously 
mentioned, is a possible mediator after ST18 KD, and regulates EMT but is also the 
principal regulator of the endothelial-mesenchymal transition (EndMT). EndMT is the 
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process by which endothelial cells acquire mesenchymal phenotype leading to 
vascular remodeling and cancer progression (Cooley et al., 2014). To investigate the 
phenotype of endothelial cells lining the vascular ectasia in the ST18 KD tumors we 
are planning to perform immunohistochemistry against EndMT markers such as N-
cadherin, SLUG and smooth muscle actin. 
EndMT also contributes to the formation and progression of cerebral cavernous 
malformation (CCM) through increased TGFβ signaling (Maddaluno et al., 2013). 
CCM lesions are formed by enlarged blood vessels that result in cerebral hemorrhages 
reminiscent of the morphological alterations in tumor vessel after ST18 KD. 
Interestingly, ST18 is a member of the NZF/MyT family of zinc-finger transcription 
factors involved in development and homeostasis of the nervous system (Yee and Yu, 
1998): it could thus be interesting to investigate the expression of ST18 during the 
onset and progression of CCM disease. 
The vascular endothelial growth factor (VEGF) pathway is a critical pro-angiogenic 
factor and has an important role in increased vascular permeability and endothelial 
migration during angiogenesis (Esser et al., 1998). High concentrations of VEGF, as 
suggested by our RNAseq analysis after ST18 KD, have been associated to fusion of 
vessels, which results in abnormally large lumens (Drake and Little, 1995). 
Altogether, we hypothesize that the mechanisms by which ST18 silencing leads to the 
vascular malformations present in subcutaneous tumors may be a consequence of 
VEGF and/or TGFβ and MEF2 signaling (Fig. 4.2). However, we cannot discard the 
possibility that tumor necrosis induced after ST18 KD might indirectly lead to 
alteration of the tumor vasculature. 
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Our study suggests that ST18 is induced by different inflammatory signals, providing 
a possible explanation for ST18 expression in subcutaneous tumors and not in cell 
culture where inflammatory mediators are not present. The role of inflammation in 
driving tumorigenesis and subsequently EMT has been widely studied. In this setting, 
our work suggests that inflammation-induced ST18 constitutes a negative regulatory 
loop that prevents EMT in conditions that would otherwise support it: abrupt 
knockdown of ST18 would thus lead to a rapid and concerted induction of EMT, as 
achieved in our tumor model (Fig. 4.3). We hypothesize that ST18 may have a dual 
role in controlling cancer onset and progression: on one hand, as documented in this 
report, ST18 plays a crucial role in tumor development and maintenance; on the other 
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it may also acts as tumor suppressor by inhibiting EMT through different mediators 
such as TGFβ and MEF2 signaling (Fig. 4.3). This context- or stage-dependent action 
of ST18 may help rationalizing the apparently contradictory reports that dubbed it 
either as a tumor suppressor or an oncogene in different types of tumors. Based on the 
results presented here, impinging on ST18 signaling responses could represent a 
relevant therapeutic strategy in liver cancer. 
Figure 4.3: Schematic representation of the dual role of ST18 in liver cancer.  
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5. SUPPLEMENTARY TABLES 
 
Table S1: Differentially expressed genes (DEGs) UP in ST18 KD tumors.  
We identified 677 DEGs UP  regulated genes in ST18 KD tumors as those ones that 
have a log2FC > 0.5 and p-value < 0.05.  
 
 
gene$name log2FC gene$name log2FC gene$name log2FC
Ildr2 1.48 Ak1 0.91 Col8a1 3.21
Gm3893 1.69 Aldh1a1 1.66 Col1a1 0.64
Tigit 0.99 Aldh3a1 2.20 Cplx2 0.50
Lrrc19 0.76 Prelp 1.30 Cryab 2.39
Mir1895 1.49 Alpk3 1.59 Csf1r 0.61
Fam46b 1.26 Aox1 0.86 Vcan 1.29
3425401B19Rik 1.99 Cd5l 2.67 Csrp3 2.87
Slco2b1 1.10 Apobec1 0.65 Ctsh 0.89
Cyp4v3 1.16 Synpo2 1.56 Ctss 0.60
Myzap 1.44 Arnt2 1.39 Cybb 0.59
Dnm3 1.33 Atp2a1 1.74 Cyp1b1 2.65
Cyp27a1 1.23 Slc7a2 0.87 Cd55 2.27
Pld4 0.59 Bach2 0.50 Dclk1 1.72
Akr1c14 1.76 Bicd1 0.82 Dcn 2.14
Csdc2 2.03 Smyd1 1.95 Dmd 2.31
Ankrd12 0.60 Serping1 1.24 Dok2 0.72
Kazald1 0.93 C3 1.29 Dpep1 2.52
Mylk 0.69 Cacna1g 0.51 Dpp4 2.09
Sema3d 1.92 Cacna1s 2.22 Ebf1 1.06
Galnt16 2.28 Cacna2d1 0.78 S1pr1 0.60
Als2cr12 1.53 Car3 2.33 Eef1a2 2.91
Ms4a7 1.46 Casp12 0.96 Emr1 0.79
Mybpc1 2.54 Casp6 0.52 Eno3 0.52
Itga1 0.96 Casq1 2.03 Epas1 0.77
Art4 1.94 Casq2 1.47 Epb4.1l3 1.73
Manba 0.76 Cav1 0.50 Epha3 3.79
Pp2d1 0.94 Cbr2 1.19 Ptprv 1.26
Scn2a1 1.31 Cd1d1 0.76 Celf2 0.80
Scn4a 1.85 Cd34 0.68 Mecom 0.65
Slc8a3 1.17 Cd36 0.95 Ppp1r3a 2.45
Abca1 0.75 Cd59a 1.22 F8 0.77
Lyve1 2.10 Cdh11 1.09 Sesn1 0.72
Acta1 1.76 Cdh3 1.10 Fcna 1.11
Brdt 0.82 Cfh 1.78 Fgf1 0.77
Hsd17b11 0.72 Chl1 2.66 Fgf7 1.67
Actn2 2.63 Ckm 2.19 Fhl1 2.46
Actn3 2.23 Clca1 1.14 Figf 1.33
Acta2 0.64 Ccr2 1.17 Fkbp7 0.58
Cygb 0.78 Col11a1 3.27 Fli1 1.01
Adam12 0.87 Col12a1 2.33 Fmn1 0.95
Adam22 1.13 Col14a1 1.49 Fmo1 1.42
Add2 0.81 Col15a1 1.09 Fmod 2.76
Adssl1 0.88 Col4a5 1.01 Aff2 1.28
Acan 2.60 Col5a2 0.88 Asb14 1.74
Angpt1 1.82 Col6a2 0.56 Folr2 1.27
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gene$name log2FC gene$name log2FC gene$name log2FC
Frk 1.42 Maf 0.99 Ptpn22 1.33
Fst 1.98 Il17rd 0.65 Ptprb 0.72
Gas6 0.96 Masp1 0.67 Ptprd 1.80
Gas7 1.33 Mb 1.69 Ptprk 0.76
Ggh 0.76 Mcf2l 0.69 Fam211b 1.64
Ghr 0.77 Mcpt4 2.45 Ptrf 0.62
Gjb3 1.57 Cma1 1.52 Pvalb 3.53
Gnal 1.11 Tpsb2 1.59 Pygm 0.99
Gnb4 0.64 Mef2c 1.19 Reps2 0.92
Gpc3 2.57 Meg3 1.68 Robo1 1.03
Gpr65 1.26 Mme 2.54 Rpgr 0.56
Gpm6b 1.32 Mrc1 0.92 Ryr1 1.65
Gpx3 1.19 Myh11 1.00 S100a4 0.78
Gsta4 1.18 Myh2 2.97 Scn7a 3.05
Gstm2 0.62 Myh3 2.52 Ccl11 2.38
H2VAb1 0.80 Myh4 4.95 Ccl8 1.65
H2VEb1 0.76 Myh8 2.46 Ccl9 0.84
Mr1 0.69 Myl4 1.38 Cxcl12 0.79
Hmgcs2 1.60 Myl1 2.47 Sdpr 0.98
Hrc 2.11 Mylpf 2.65 Sema3a 0.92
Sdc2 0.71 Myo6 0.53 Sema3c 1.97
Slc6a4 1.35 Myog 2.22 Sema5a 0.63
Igf1 2.64 Myom1 1.09 Sepp1 1.03
Itga4 0.61 Myom2 2.78 Sfrp1 2.67
Itih2 1.29 Naip2 0.76 Sfrp4 1.73
Itm2a 1.75 Ncf1 0.77 Sgce 0.51
Sspn 0.51 Neb 2.41 Sorbs3 1.15
Lama2 1.58 Nov 1.65 St6gal1 0.70
Anpep 0.52 Nrap 2.77 Sla 1.26
Lepr 0.78 Ntrk2 1.31 Slc8a1 1.02
Lifr 0.53 Ocln 1.11 Slit2 1.78
Lox 3.03 Ogn 1.14 Slit3 2.62
Loxl1 1.31 P2rx6 1.71 Sod3 3.23
Loxl3 0.70 Pappa 1.91 Sox5 0.75
Ltbp2 2.10 Pbx1 0.59 Sox6 1.50
Lum 2.20 Pcsk5 3.15 Serpinb6b 1.85
Lxn 0.58 Pde1a 0.60 Serpinb9 0.82
BC002163 0.90 Per2 0.85 Pknox2 1.18
Ly6c1 0.90 Phex 1.34 Aph1b 0.72
Papln 0.90 Prkcb 0.54 Btla 1.64
Tlr7 1.35 Pkia 1.93 Fam180a 1.93
Tlr8 1.93 Plcb4 0.74 Phldb2 0.72
Eltd1 0.73 Pltp 1.23 Etl4 1.47
Asic3 0.77 Prrx1 1.72 Itih5 0.51
Havcr2 1.54 Inpp5k 0.52 Dock10 1.17
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gene$name log2FC gene$name log2FC gene$name log2FC
Pamr1 1.83 Tnnt2 1.55 Neil3 0.52
Efhb 1.40 Tnnt3 1.60 Inpp4b 1.38
Tifa 0.62 Tpd52l1 1.06 Zfp810 0.70
Chpt1 0.75 Ttn 2.36 Adamts15 1.77
Fam46a 1.33 Unc5c 1.58 Zbtb16 1.09
Itga10 1.43 Itgbl1 3.77 Plscr4 1.08
Ankrd35 2.26 Vcam1 0.61 Acpl2 0.75
Il20rb 0.89 Abra 2.65 Ppp2r3a 0.57
Rassf4 0.90 Wisp2 1.52 Arhgef9 0.80
Tagln 0.91 Tmem44 0.56 Stard8 1.33
Lgi3 1.54 Xirp1 3.81 Klhl4 1.04
Xist 0.91 Xk 0.81 Tceal1 1.54
Tcap 2.68 Zfp758 0.56 Col23a1 1.44
Tcea3 1.36 Ankrd29 1.52 Adam23 2.29
Cilp 3.60 Fhod3 1.65 Adamts5 1.08
She 0.88 Alpk2 2.17 Aplnr 1.51
Aldh5a1 0.86 Pla2g16 1.18 Sdk2 1.27
Zmat1 0.91 Myrf 1.15 Akap6 1.01
Pik3ip1 0.78 Slc6a20b 1.06 Macc1 0.96
Ccdc85a 1.59 Tmem252 1.20 Pde4d 0.84
Efemp1 3.10 Pgm5 1.95 Gpr34 0.83
Adamts2 1.18 Siae 0.67 Grem2 2.04
Wnt9a 1.84 Ablim1 0.64 Kctd12 0.75
Tef 0.75 Igfn1 1.93 Lamc3 1.11
Tek 1.25 C130074G19Rik 1.08 Lynx1 1.83
Adap2 1.01 Zfp2 0.61 Tspyl5 1.60
Abca9 1.35 Dnah7b 1.10 Mid2 0.87
Pqlc3 0.82 Zfp90 0.54 Gpr156 1.49
Ankmy2 0.53 Gsn 0.63 Sulf1 1.48
Stxbp6 1.48 Klhl41 1.81 Xirp2 3.82
Tfpi2 2.33 Mylk2 1.66 Pde5a 1.34
Rapgef5 0.68 Ctso 0.81 D630039A03Rik 1.09
Tgfb2 1.15 Slc16a4 0.71 Myom3 2.27
Thbs2 1.21 5730409E04Rik 1.00 Gpr133 2.94
Thbs3 0.59 Cyp26b1 1.51 A430033K04Rik 0.60
Thbs4 2.94 Frmd4b 0.91 Gimap8 0.60
Thy1 1.25 Gxylt2 0.92 Zfp791 1.53
Pde8b 0.88 A2m 2.51 Abcc12 1.68
Gcnt4 1.08 Clec12a 0.95 Nxpe4 0.63
Scara3 0.80 Ccdc136 0.50 Layn 1.00
Tnnc2 3.01 B3gnt8 0.68 Klhl31 1.99
Tnfrsf11a 0.85 Mybpc2 2.58 Col6a6 1.69
Tnni1 1.46 Ano5 2.06 Zfp300 0.62
Tnni2 2.51 Synm 0.75 Zc4h2 0.67
Tnnt1 1.37 Spon1 1.93 Mum1l1 0.98
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gene$name log2FC gene$name log2FC gene$name log2FC
Tbc1d8b 0.65 Mcc 0.63 Hmcn1 1.18
Olfr920 1.98 Ankrd44 1.03 Ccdc141 1.16
Srgap3 1.69 Accs 0.58 Pdgfc 1.48
Ceacam1 0.91 Fat4 1.43 Plxnc1 0.81
Prnd 1.63 AI464131 0.70 Cpxm2 2.13
Ror1 1.64 Frem1 1.02 Fmo2 2.01
Gm1564 1.72 Col8a2 3.20 Dgke 0.53
Abcd2 1.24 9530026P05Rik 0.67 Plac1 1.52
Abat 0.83 Rnf150 1.01 Dpt 0.70
Dysf 0.54 Dixdc1 0.95 Cyp2d22 0.78
Kif26b 0.83 Cntln 0.74 Ctsf 0.79
Islr 1.76 Txlnb 1.01 Vmn2r1 1.32
Clec4a1 1.11 Obscn 2.34 Ankrd2 2.52
Pon3 0.80 Fam189a2 1.51 Serinc4 0.97
Maml2 0.72 Atp2b4 0.64 Usp29 1.92
Amica1 1.17 Nxpe5 1.89 Slc43a3 1.08
Pdk4 2.61 Zfp667 0.60 Rnase4 1.09
Nrep 0.69 Ecm2 0.85 Myot 3.44
Timd4 1.54 Mettl21c 1.18 Fxyd6 0.94
Vsig4 2.17 Trim63 1.85 Tmem8 1.45
Spin2c 1.33 Trim72 1.83 Gucy1a3 0.96
Tlr13 1.00 Nox4 1.23 Trp53inp1 1.18
Rabgap1l 0.61 Mfap5 3.35 A230073K19Rik 0.80
Ndrg2 0.67 Postn 2.73 Zfp963 0.67
Hspb7 2.45 Dkk3 1.84 Nrgn 0.66
Pde7b 0.97 Hmgn5 0.97 Smoc2 1.08
Angptl3 0.70 C1s 2.05 Gpr88 1.86
Zfp354c 0.75 Srpx 2.15 Ms4a8a 1.95
Pik3cg 0.87 Ccdc39 1.12 Lpin3 0.96
Pcmtd1 0.66 D7Ertd715e 0.90 Slc9a3r2 0.55
Cxxc4 0.87 Ldlrad4 0.53 Smpx 2.22
Zfp182 0.65 Cd300lg 0.69 Fbxo36 0.93
Zfp944 0.63 Lurap1l 1.42 Mustn1 1.61
Fsd1l 0.50 Dlg3 0.64 Fam134b 0.68
Dsel 0.69 Pdlim3 2.98 Mgst3 1.14
Apba1 1.55 Hif3a 0.85 Rwdd3 1.02
Olfml2b 1.55 Gria3 2.79 Dcbld1 0.51
Fbxl13 1.30 Tlr5 1.58 Aspn 1.27
4930412C18Rik 1.47 Pcdh7 1.02 Tab3 0.51
Scai 0.61 Ctnnal1 0.95 Ptplad2 0.84
Glt28d2 1.44 Cpq 0.73 Gm9079 1.15
P4ha3 2.36 Mtmr7 0.79 Snord123 0.76
Abi3bp 2.15 Slc4a4 1.82 Cir1 0.56
Zhx3 0.55 Hpgds 0.64 2310030G06Rik 1.26
Lrrn4 1.31 Kalrn 0.94 Fam210b 0.87







gene$name log2FC gene$name log2FC gene$name log2FC
Gpx7 1.56 Pgm2l1 0.55 Glt8d2 1.06
Zfp606 0.53 4931406C07Rik 0.57 Purg 0.75
3632451O06Rik 2.23 Scara5 1.43 Cep128 0.56
Adck3 1.03 Arhgap42 0.59 Zfp820 0.63
Plxdc2 0.89 Gdpd2 2.07 Calml4 1.05
Tbc1d23 0.51 Zfp949 0.51 Rian 1.33
Fibin 1.46 4930506M07Rik 0.92 4930578C19Rik 1.32
Zfp788 0.54 Rarres2 1.57 Mfap4 1.27
4930523C07Rik 1.54 Rbm43 0.52 Asb5 1.62
Rnf125 0.98 Armcx3 0.82 Tbx18 0.86
Fbxo32 0.71 Lrrcc1 0.76 Cep112 0.70
S100a16 1.02 Osbpl3 0.75 Daam2 1.09
Rgs10 0.81 Ccdc19 0.69 Prss23 1.00
Tmem100 2.92 Epn3 0.96 Cmya5 2.56
Ccdc80 0.96 Klhl40 1.67 Ckmt2 1.58
Spata6 0.61 Palld 0.72 Trdn 3.94
Murc 0.96 Zc2hc1c 0.64 Rab36 0.70
Cep70 0.69 2210408I21Rik 0.56 Il33 0.87
5031426D15Rik 0.88 Ttc30b 0.69 Anks1b 1.22
Gstm7 0.96 Usp13 1.70 Adamtsl1 2.47
Cthrc1 4.04 Angptl1 0.98 Adamtsl2 1.33
Fndc1 2.87 Pard3b 1.27 Ypel2 0.57
Fam198b 0.81 Mblac2 0.62 2810055G20Rik 0.80
Lrrc16a 1.10 March1 1.21 Zfp449 0.64
Synpo2l 1.64 3110007F17Rik 0.71 Hdac9 0.66
Srpx2 3.23 Clec4a3 1.07 Wbscr27 0.68
Pdgfrl 2.29 Bmper 1.65 Trim2 0.52
Mypn 2.20 Arhgef6 0.66 C1qtnf3 3.90
Nexn 0.79 1700049G17Rik 0.63 Tnxb 1.01
Smim1 1.14 Vgll3 2.34 Trem2 1.40
Cd209f 2.80 Ms4a6c 0.60 Tktl1 1.51
Cmbl 0.82 Zbtb8a 0.57 Sytl2 1.98
Pir 0.81 Rftn2 0.97 Bicc1 0.54
Ms4a6b 0.84 Nphp3 0.65 Crispld1 2.31
Wnk4 0.92 Plce1 0.86 Cd163 0.66
2810403D21Rik 0.99 Ifltd1 1.71 Lmod2 2.92
Ogfrl1 0.61 Npl 0.98 Smarca1 1.85
Gcc2 0.52 F13a1 1.27 Peli2 0.59
Ica1l 0.84 Lrguk 1.08 Trim7 0.89
Filip1 0.97 Myo18b 2.85 Trim9 1.84
Gulp1 1.01 Cep72 0.64 Ophn1 1.42
Medag 2.08 Lrrc15 2.16 Col4a6 1.14
Tspan2 1.84 Lrrc17 0.85 Prg4 1.21
Klhl30 1.60 Zfp943 0.54 Pid1 0.81
P2ry12 1.47 Hhatl 1.61 Atp1a2 1.12gene$name log2FC
Myl9 0.69
Cercam 1.13
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Table S2: Differentially expressed genes (DEGs) DOWN in ST18 KD tumors.  
We identified 467 DEGs DOWN  regulated genes in ST18 KD tumors as those ones 
that have a log2FC < -0.5and p-value < 0.05.  
 
gene$name log2FC gene$name log2FC gene$name log2FC
Fam129c /0.76 Hrk /1.77 Hspa1b /1.05
Isg15 /0.89 Bop1 /0.50 Ier3 /0.81
1110002L01Rik /0.81 Bsn /0.73 Ier5 /0.55
Kti12 /0.55 Hyou1 /0.63 Cxcl10 /1.69
Akna /0.68 Car6 /1.85 Ifit1 /0.76
Snord93 /0.57 Cbs /0.80 Ifrd2 /0.76
Epg5 /0.70 Entpd6 /0.59 Il11 /2.41
Dos /0.76 Cdkn1a /0.65 Il1b /1.48
Noc4l /0.55 Cebpb /0.91 Isl1 /1.13
Psph /0.72 Cish /0.71 Itgal /1.08
Chchd10 /1.47 Plk3 /0.76 Jag2 /0.81
E130012A19Rik /1.07 Atf6b /0.67 Jak3 /0.52
Tubg1 /0.57 Crmp1 /0.84 Jun /0.78
Pcnxl3 /0.52 Csf3 /1.73 Junb /0.52
Tecpr2 /0.73 Csf3r /1.46 Kit /0.62
Cdk20 /0.65 Csn3 /1.06 Arhgef2 /0.56
Gpsm3 /0.56 Cxadr /0.93 Lck /1.23
Wdr90 /0.50 Ddit3 /1.02 Lcn2 /1.27
LOC106740 /0.54 Dll1 /0.71 Lif /1.11
Slc39a3 /0.62 Eif2b4 /0.59 Rtn4ip1 /0.74
Rrp12 /0.98 Eno1 /0.55 Bbc3 /0.68
Yars /0.50 Epha2 /0.71 Hook2 /0.61
Guca1b /1.47 Etv2 /2.12 Acot2 /0.76
Atf5 /1.05 Fanca /0.53 Mef2b /1.62
Cth /0.89 Fhl3 /0.50 Mknk1 /0.62
Shmt2 /0.65 Foxc2 /1.40 Mthfd2 /0.64
Gpt2 /0.63 Fosl1 /1.08 Mybl2 /0.52
Atad3a /0.51 Fosl2 /0.84 Ppp1r15a /0.91
Nabp1 /0.88 Ncs1 /0.55 Ndrg1 /0.72
Pwp2 /0.50 Fut1 /1.67 Nfil3 /0.95
Dxo /0.56 G0s2 /1.55 Nfkb2 /0.64
Aatk /0.55 Gaa /0.54 Nnmt /1.07
Chrnd /1.24 B4galnt2 /0.77 Slc11a2 /0.53
Impa2 /0.53 Gbp2 /0.63 Sigmar1 /0.52
Adam15 /0.53 Glp1r /0.82 P2ry2 /0.99
Adora1 /1.16 Glrp1 /1.14 P4ha2 /1.00
Avil /1.91 Slc6a9 /0.93 Pcx /0.73
Alpl /0.68 Got1 /0.61 Pdgfa /0.61
Aqp3 /0.99 Gpaa1 /0.64 Pfkl /0.52
Klf16 /0.73 Cxcl1 /1.13 Pim1 /0.52
Atf3 /1.23 Gys1 /0.78 Pitpnm1 /0.55
Slc7a1 /0.74 Hap1 /1.14 Por /0.50
Bcat1 /0.77 Hdc /1.48 Ppard /0.72
Bcl6 /0.66 Hbegf /0.56 Scand1 /0.83
Mrps6 /0.52 Hoxb9 /1.97 Prodh /0.54
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gene$name log2FC gene$name log2FC gene$name log2FC
Prss12 /0.94 Tmem194 /0.74 Rnd1 /1.30
Ptgir /0.85 Nomo1 /0.52 Soat2 /1.39
Hps4 /0.61 Wwc1 /0.80 Wfs1 /0.71
Ptprn /0.56 Mars2 /0.57 Uhrf1bp1 /0.60
Nacad /1.25 Gm17296 /0.64 Ppp2r5b /0.64
Rad9a /0.55 Slc39a14 /0.62 Rin1 /0.66
Hspa1a /1.14 Taf1c /0.67 Tmem185b /0.71
Rapsn /1.05 Fbxo42 /0.53 Qsox2 /0.53
Rasal1 /0.87 Zfp598 /0.70 Oct4 /0.64
Relb /0.79 Disp2 /1.11 Coq4 /0.52
Rfng /0.57 Tcof1 /0.83 Slc25a25 /0.51
Polr1b /0.51 Arid5a /0.82 P2rx3 /1.32
Rps6ka2 /0.59 Csrnp1 /0.58 Rhov /1.58
S100a8 /1.33 Lrrc20 /0.52 Mavs /0.53
S100a9 /1.15 Polrmt /0.59 Trib3 /1.36
Ccl2 /0.76 Sbno2 /0.61 Ppp1r16b /0.75
Ccl20 /2.30 Aldh1l2 /0.87 Fitm2 /0.56
Ccl3 /1.84 Phlda1 /0.63 Slc35c2 /0.66
Ccl7 /0.82 Gemin5 /0.56 Helz2 /0.66
Cxcl2 /1.26 Kdm6b /0.58 Ciart /1.08
Sell /1.22 Wrap53 /0.58 6330416G13Rik /0.55
Sema4d /0.72 Neurl4 /0.57 Sesn2 /1.45
Sema6b /0.80 BC030867 /0.51 Zbtb40 /1.04
Siah2 /0.90 Rhbdf2 /0.74 Cox18 /0.53
Clpb /1.00 Engase /0.78 Paqr3 /0.83
Slc1a5 /0.59 Terc /0.99 Agpat9 /1.01
Slc20a1 /0.54 Tgfa /0.65 Oasl1 /1.02
Slc2a1 /0.79 Lhfpl2 /0.59 Gcn1l1 /0.51
Slc2a3 /0.68 Mrps27 /0.65 Aimp2 /0.51
Slc7a5 /0.75 Tll1 /0.84 Lmtk2 /0.50
Slfn4 /1.54 Cd40 /0.56 H2afj /0.88
Slpi /1.79 Cmpk2 /1.37 Zfp428 /0.59
Smarcb1 /0.51 Ung /0.53 Zfp574 /0.63
Sorl1 /0.95 Upp1 /0.51 Kctd13 /0.52
Urb1 /0.73 Vars /0.55 Piezo1 /0.50
Srm /0.61 Vegfa /0.71 Igsf9b /1.15
Dhx37 /0.78 Vldlr /0.56 Lingo3 /1.75
Star /0.63 Them6 /1.08 Gadd45g /0.65
Stat1 /0.53 C030006K11Rik /0.86 Gdf15 /2.42
Stc2 /1.46 Arhgap39 /0.61 Cacna1i /1.03
Alg3 /0.62 Ankrd54 /0.57 Oasl2 /0.89
Slc25a38 /0.66 Ttll12 /0.51 Sigirr /0.68
Stra6 /1.16 Wars /0.62 Dusp5 /0.84
Pycr1 /1.03 Pim3 /0.63 Map2k3os /0.68
Tbc1d25 /0.63 Adm2 /1.88 Usp18 /1.06
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gene$name log2FC gene$name log2FC gene$name log2FC
Dhrs9 /0.86 Ndufa4l2 /0.91 Sdf2l1 /0.85
Fam171b /1.46 Itprip /1.16 Ptges /0.55
Slc1a7 /1.71 4930404N11Rik /0.58 Fndc4 /0.67
Trim30b /1.24 Prr7 /0.97 D330041H03Rik /0.82
Retnlg /1.36 Gm5483 /1.68 Rgcc /0.59
Spata2 /0.51 Heatr2 /0.54 Lyrm9 /0.64
Map2k2 /0.53 Slc28a1 /1.93 Dus2 /0.71
Slc7a11 /1.04 Fbxl8 /0.73 Dhrs7 /0.50
Stfa2l1 /1.42 Capn15 /0.59 Sac3d1 /0.55
Cln8 /0.57 Cdk2ap2 /0.62 Tmem238 /0.95
Gcat /0.61 Coq5 /0.55 Timm50 /0.62
Zfp346 /0.59 Pvr /0.51 Acp6 /0.54
Slc4a11 /0.97 Agpat5 /0.54 Ctu2 /0.65
Ecsit /0.51 Stbd1 /0.98 Cdt1 /0.56
Map1s /0.60 Slc52a2 /1.06 Dedd2 /0.75
Rab6b /0.94 Cntnap1 /0.72 Ankrd33b /0.69
Cars /0.52 Banp /0.66 Eepd1 /0.57
Tbl2 /0.53 Tomm40 /0.50 Dph2 /0.71
Rrp9 /0.51 Bysl /0.83 Prpsap1 /0.71
Desi1 /0.60 Irf7 /0.90 Jagn1 /0.54
Znhit2 /0.73 Nup210 /1.31 Rtp4 /0.75
Pmm1 /0.71 Slc1a4 /0.96 Rab39b /0.68
Fbxl6 /0.52 Agpat1 /0.57 Dgat2 /0.99
Zbtb18 /0.78 Gtpbp2 /0.53 Asprv1 /1.57
Tor2a /0.78 Rabggta /0.54 Pdf /1.19
Ptpn7 /0.54 Scamp4 /0.65 Mid1ip1 /0.69
Maats1 /1.37 Extl1 /2.02 Fam173b /0.51
Cass4 /1.61 Adar /0.65 Otub2 /1.16
Tmem154 /1.14 Pard6a /0.94 Coa4 /0.82
Trmt61a /0.59 Txn2 /0.62 Leprotl1 /0.52
Apol11b /2.05 Sphk2 /0.56 Slc25a22 /0.78
Ptrh1 /1.00 Fgf21 /1.98 Ccdc163 /0.51
Lcmt2 /0.56 Pigo /0.62 Ints1 /0.56
Slc5a6 /0.56 Pdxp /0.70 Tmem109 /0.51
Trim66 /1.23 Dolpp1 /0.61 Chac1 /1.55
Hapln4 /1.34 Apba3 /0.68 Ydjc /0.52
Ppp1r13l /1.03 Rsad2 /1.27 Comtd1 /0.69
Trim46 /1.34 Nelfb /0.61 Mocs3 /0.68
Nckap5l /0.50 Rrs1 /0.60 Bst2 /0.59
Dnph1 /0.60 Pnkp /0.56 Ap5s1 /0.83
Ap5b1 /0.78 Fetub /0.97 2310061I04Rik /0.52
5830416P10Rik /0.87 Nrip2 /1.24 Cad /0.53
Vgf /2.54 Fads3 /0.87 Eif1ad /0.56
Kctd16 /1.69 Fam43b /1.67 Ufsp1 /0.87
Cdsn /1.53 Fam129a /0.75 Rnf126 /0.61
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gene$name log2FC gene$name log2FC
Cactin /0.51 Aacs /0.51
Cd3eap /0.53 Ern1 /0.71
Reep6 /1.44 Recql4 /0.85
Steap1 /0.67 Slc16a3 /1.00
Dhrs13 /0.58 Slc12a9 /0.65
Slc25a33 /0.95 Dnaja3 /0.72
Angptl6 /1.54 Pcdhgb2 /0.57
Spef1 /0.55 Pcdhga1 /0.63
Mus81 /0.50 Pcdhga2 /0.84
Ulk3 /0.66 Pcdhga4 /0.64
Tysnd1 /0.61 Nkd1 /0.99
Osgin1 /0.92 Cnnm4 /0.79
Cyb5r1 /0.91 Wbscr16 /0.57
Usp36 /0.84 D930048N14Rik /0.91
Faim2 /1.07 Nat10 /0.51
Tspyl4 /0.95 Abtb2 /0.58
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